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Introduction
1. Introduction
1.1 Tumor immunology
According to the World Health Organization, cancer was the third leading 
cause of death in high-income countries in 2008 (source: WHO, list of leading 
causes of death 2008). The first and second leading cause of death were 
cardiovascular and cerebrovascular diseases, respectively. In recent years the 
therapy of infectious diseases and cardiovascular diseases strongly improved, 
thereby increasing remarkably the average life expectancy in countries with 
modern medical care. In contrast, the incidences of nearly all types of cancer 
dramatically increased in the last decades in these countries. According to 
the American Cancer Society, the increase in cancer incidences is mostly due 
to the demographic changes in Western countries (source: American Cancer 
Society, cancer facts & figures 2012). Therefore, efficient treatment of cancer 
has become one of the most important challenges for modern medicine.
Cancer always derives from a single initially harmless cell. After accumulating 
several mutations, this cell can give rise to a tumor, a process called malignant 
transformation. In order to become a tumor, tumor cells must gain certain 
abilities such as the independence from growth factors and immortalisation. In 
the past decades it became clear that in addition the tumor cells must acquire 
mechanisms to circumvent immune surveillance in order to develop to a clinically 
relevant tumor. Cancer development is thought to be a dynamic process which 
is accompanied by immunoediting. This process is divided in the three phases: 
elimination, equilibrium and escape (Dunn et al., 2002, 2004). In the first phase, 
also called immune surveillance (Burnet, 1970), potential tumor cells are recog-
nized and killed by the immune system. The second phase, the equilibrium, 
follows if some degenerated cells survived the first phase. As a consequence 
of selection imposed by the immune system these cells accumulate mutations 
and intracellular changes that promote their survival and suppress their killing. 
If one of these cells has gathered enough mutations to escape immune surveil-
lance, the final phase is reached. In this phase the selected tumor cell can grow 
and cause clinically apparent cancers (Shankaran et al., 2001).
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One of the major difficulties of cancer therapy is that all tumor cells must be 
removed and destroyed to cure a patient because even one remaining tumor 
cell can grow again to a lethal tumor. The standard treatment of cancer today 
is surgery, chemotherapy and radiation. Although these clinical methods 
became more effective in the last decades, a complete tumor remission and 
thereby associated long time survival of the patients is usually not guaranteed. 
In the last few years cancer immunotherapy has become more and more 
promising as fourth possibility of treating tumor patients. The fundamental 
idea of immunotherapy is to reprogram the immune system in order to induce 
an effective immune response against an established tumor.
In untreated tumor-bearing patients, T cells specifically directed against 
tumor cells can be found. These T cells express T cell receptors (TCRs) that 
recognize certain tumor-specific tumor-associated antigens (TAAs). TAAs are 
antigens that generally are expressed exclusively by cancer cells and not by 
other healthy tissue cells. Such antigens develop in tumor cells due to inappro-
priate protein expression or mutated proteins that generate novel  epitopes 
(Williamson et al., 2006). For example, in many tumors a mutation of the cell 
cycle molecule p53 generates a novel antigen epitope which in turn is only 
presented by these tumor cells (Mayordomo et al., 1996). Indeed, cytotoxic 
T cells, specific for certain TAAs and thereby capable of tumor cell killing, can 
be found in the tumor tissue of many patients. High tumor infiltration rates 
of these cells are often associated with better survival rates of the patients 
(Naito et al., 1998). 
Nevertheless, since immune-mediated spontaneous rejections of established 
tumors are rare, TAA specific cytotoxic T cells generally fail to eliminate 
the tumor. This implies that the tumor can develop mechanisms to evade 
an effective immune response. Today, there are many mechanisms known 
to contribute to this evasion. For example, tumors can produce immuno-
suppressive cytokines such as transforming growth factor-beta (TGF-β) that 
suppresses cell-mediated immunity (Tada et al., 1991). Another way in which 
the tumor can block an anti-tumor immune response is by recruiting regula-
tory T cells (Tregs). These cells are known to suppress the function of other 
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immune cells such as cytotoxic T cells and thereby block anti-cancer immunity 
(Betts et al., 2006). Increased numbers of Tregs have been found in the blood 
and the lymph nodes of tumor patients (Colombo et al., 2007) as well as in 
the tissue of several human tumors (Betts et al., 2006). In the last years it was 
shown that high numbers of tumor-infiltrating Tregs are associated with poor 
prognosis for tumor patients (Curiel et al., 2005; Gobert et al., 2009). Thus, 
manipulating the balance between intratumoral Tregs and cytotoxic T cells 
seems to be a promising new target for cancer therapy.
The advantage of using the host immune system for destroying cancer cells 
in patients is the potential detection and elimination of even single tumor 
cells in almost every part of the human body. In contrast to chemotherapy, 
an immune system mediated tumor cell killing could be very specific and 
side effects could be reduced. However, the human immune system is very 
complex and manipulating its mode of action is challenging and could be 
dangerous. One prominent example, demonstrating the risks of immune 
therapy, is the phase 1 clinical trial of the anti-CD28 monoclonal antibody 
TGN1412. This antibody was intended for the treatment against B cell chronic 
lymphocytic leukemia and rheumatoid arthritis. After successful trials in mice 
and monkeys the antibody was used for a phase 1 trial in human volunteers. 
Instead of mild effects in healthy donors, as predicted, strong side effects 
caused by a cytokine storm were observed in all test persons (Suntharalingam 
et al., 2006). 
Nevertheless, exploiting immune regulation is very promising and has great 
potential for treating many human diseases including tumors. Currently, 
there are many immune regulating drugs in clinical trials or even on the 
market. One example are antibodies directed against cellular receptors 
that regulate cell proliferation such as cetuximab, a monoclonal antibody 
directed against epidermal growth factor receptors (EGFR). This antibody 
is used to treat colorectal cancer (Karapetis et al., 2008) and head and neck 
cancer (Bonner et al., 2010). CTLA-4 blocking antibody is another example 
for generating an effective anti-tumor immune response in patients. It 
inhibits Treg function and prevents inactivation of activated effector T cells. 
Thereby, anti-CTLA-4 antibody treatment reduced cancer progression in 
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patients with metastatic melanoma (Hodi et al., 2011; Phan et al., 2003).
Another approach of clinically applied immunotherapy is the adoptive transfer 
of T cells. Therefore, T cells from tumor-bearing patients are isolated, selected 
for tumor-specific cytotoxic T cells, expanded ex vivo and finally re-injected 
into the patient (Rosenberg et al., 1994; June, 2007). 
1.2 Regulatory T cells and tumor immunity
1.2.1 Regulatory T cell subsets and function
In general, there are two main subtypes of regulatory T cells (Tregs) in mice 
and humans. These two subtypes are natural Tregs (nTregs) and induced Tregs 
(iTregs). Both express forkhead box p3 (FOXP3), a transcription factor that is 
required for suppressive function. Natural Tregs develop in the thymus from 
CD4+ thymocytes. In contrast to conventional T cells, nTregs are selected in 
the thymus by high-affinity binding to a self antigens. Thus, nTregs express 
TCRs against self antigens. On the other hand, iTregs develop in the periphery 
from uncommitted conventional CD4+ T cells. This second Treg subset is a 
heterogeneous group that consists of at least three distinct subgroups. Most 
of the iTregs found in the periphery belong to the first subgroup. These cells 
develop through the conversion of conventional T cells into iTregs induced 
by TGF-β, IL-2 and APCs that express low dose of antigen in the absence of 
co-stimulatory molecules. The second subgroup of iTregs, the TR1 cells, are 
induced by high concentrations of IL-10 and secrete TGF-β and IL-10 after 
differentiation. TH3 cells represent the third subgroup. These cells seem to be 
induced by TGF-β and can be found in the mucosal immune system.
To differentiate Tregs from other T cell subsets, many cell surface markers as 
well as intracellular markers have been identified in the last decade. In mice 
the most important Treg marker is the transcription factor FOXP3 (Hori et al., 
2003). Human Tregs also express FOXP3, but in contrast to mice many human 
conventional T cells without suppressive function up-regulate FOXP3 upon 
activation (Allan et al., 2007). Beside the intracellular marker FOXP3, Tregs are 
also defined by high expression of the surface marker interleukin-2 receptor 
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α-chain (CD25), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), gluco-
corticoid-induced tumor necrosis factor receptor family-related gene (GITR) 
and lymphocyte activation gene-3 (LAG-3) as well as low expression of CD127. 
By defi nition the main function of Tregs is to regulate the function of other 
immune cells. Tregs are needed to prevent autoimmunity by eliminating self 
reactive T cells that survived thymic selection, a process called peri pheral 
tolerance (Sakaguchi, 2005). In addition, Tregs are required to prevent over-
whelming immune responses against invading pathogens. To execute all these 
tasks, Tregs have a variety of mechanisms to control other immune cells.
4) Suppression by DC/Treg interaction 
DC
Treg
T cell
CD80/86
CTLA-4
IDO
3) Suppression by metabolic disruption 
Treg T cell
IL-2CD25
T cell inactivation
TGF-β
1) Cytokine-mediated suppression
IL-35 IL-10
DC
Treg
T cell
2) Cytolysis-induced apoptosis 
Granzyme A
Granzyme B Apoptosis
Treg
Perforin
T cell
Figure 1: Mechanisms of Treg suppression. The illustration shows the modes of Treg suppres-
sion. First, Tregs can suppress DCs and T cells by secreting inhibitory cytokines. Second, Tregs release 
granzyme A and B as well as perforin to induce apoptosis in target cells. Third, CD25 expressed on 
the surface of Tregs can bind IL-2 and thereby deplete IL-2. Since IL-2 is needed by activated T cells for 
survival depletion of IL-2 leads to T cell inactivation. Fourth, Tregs mediate suppression by interaction 
with activated DCs. CTLA-4 expressed on the surface of Tregs binds with high affi nity to the DC 
co-stimulatory receptors CD80 and CD86. Thereby T cells activation by CD80 and CD86 is blocked. 
In addition, CTLA-4 binding induces IDO expression by DCs which in turn suppresses T cells. [Figure 
is adapted from an illustration published by Vignali et al., 2008]
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The mechanisms of Treg action can be divided in four categories (Figure 1). 
First, Tregs can suppress immune cells such as dendritic cells (DCs), CD4+ and 
CD8+ effector cells by secreting inhibitory cytokines such as IL-10, IL-35 and 
TGF-β (Collison et al., 2007; Letterio and Roberts, 1998; Hara et al., 2001). 
The second mechanism of Treg-mediated immune regulation is the induced 
apoptosis via cytolysis. Such as cytotoxic T cells Tregs can express granzyme A 
and B as well as perforin (Grossman et al., 2004). Suppression by metabolic 
disruption is the third mode of Treg action. For example, Tregs express high 
amounts of interleukin-2 receptor α-chain (CD25). CD25 can bind and thereby 
deplete local IL-2. This cytokine is needed by activated effector T cells for 
survival. Thus, depleting IL-2 leads to effector T cell inactivation (Thornton and 
Shevach, 1998). Finally, suppression by targeting dendritic cells is the fourth 
mode of Treg function. Unlike the other three mentioned mechanisms, this 
mechanism requires direct cell contact between Tregs and DCs. To interact 
with DCs, Tregs express high levels of CTLA-4. This surface molecule binds 
with high affinity to the co-stimulatory molecules CD80 and CD86, both being 
expressed by mature DCs. Thereby, Tregs prevent T cell activation by blocking 
and suppressing these co-stimulatory molecules (Read et al., 2000; Cederbom 
et al., 2000) and induce indoleamine 2,3-dioxygenase (IDO) release by DCs, 
which in turn initiates apoptosis in activated T cells (Fallarino et al., 2003).
1.2.2 Regulatory T cells in murine and human tumors 
In healthy persons Tregs are crucial for preventing autoimmune diseases and 
limiting immune responses against invading pathogens. Deficiency of FOXP3, 
a transcription factor essential for Treg development and function, induces a 
profound autoimmune-like lymphoproliferative disorder in mice and humans. 
Mice that lack FOXP3 are known as scurfy mice (Brunkow et al., 2001). Humans 
carrying a loss-of-function mutation on the FOXP3 gene suffer from a disease 
called immune dysregulation, polyendocrinopathy, entero pathy, X-linked 
syndrome (IPEX) (Bennett et al., 2001), a rare X-linked recessive genetic 
disorder. Since FOXP3 deficiency results in Treg defects, this severe disorders 
illustrate the importance of Tregs for maintaining immune homeostasis. 
Nevertheless, due to their immune suppressive function, Tregs are often 
harmful for tumor-bearing patients. Regulatory T cells can be coopted by 
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tumor cells to escape immune surveillance. Thereby, an effective anti-tumor 
immune response is blocked and tumor development is promoted (Betts et 
al., 2006). Since more and more Treg-specific markers were found (see above) 
in the last years, a reliable identification of these cells has become possible. 
With these markers a lot of progress has been made in investigating the role 
of Tregs in cancer patients. For instance, in many tumor-bearing patients 
increased amounts of Tregs were found in the blood and the lymph nodes 
(Colombo et al., 2007) as well as in the tumor tissue itself (Betts et al., 2006). 
In further experiments the functionality of these tumor-infiltrating Tregs 
was confirmed. By isolating these cells from freshly dissected murine and 
human tumors, their suppressive nature in regard to blocking effector T cell 
proliferation in vitro was clearly shown (Curiel et al., 2004; Zhou et al., 2006). 
These findings were also confirmed in vivo. As shown by Yu and colleagues in 
murine tumors, CD4+CD25+ Tregs actively suppress the proliferation of CD8+ 
cytotoxic T cells at the local tumor site and thereby promote tumor growth 
especially in later stages of tumor progression (Yu et al., 2005). Consistent 
with the previous findings, high amounts of tumor-infiltrating Tregs are asso-
ciated with poor prognosis and predict poor survival in human ovarian carci-
noma and breast cancer (Curiel et al., 2005; Gobert et al., 2009). 
1.2.3 Regulatory T cells as therapeutic target
According to the previously discussed findings Tregs seem to be a very prom-
ising target for anticancer therapy. Indeed, by reducing Treg function and/or 
intratumoral accumulation, therapeutic effects in tumor-bearing mice were 
observed. The therapeutic benefits of Treg depletion in tumor-bearing mice 
were first demonstrated by adoptive T cell transfer experiments in BALB/c 
athymic nude mice. Adoptively transferred CD25-depleted CD4+ cells, consid-
ered as non-Treg cells, into RL male 1 (BALB/c-derived radiation leukemia) 
tumor-bearing nude mice resulted in tumor regression. In contrast, nude 
mice treated with a non-depleted CD4+ T cell adoptive transfer died due to 
rapid tumor progression (Shimizu et al., 1999). Similar results were observed 
in tumor-bearing mice treated with an anti-CD25 monoclonal antibody. In 
these experiments, antibody-mediated CD4+CD25+ Treg depletion induced 
tumor growth retardation in murine sarcoma and melanoma (Tanaka et 
al., 2002). IL-2 immunotoxin-mediated Treg depletion is another approach 
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in mouse tumor models. This toxin mediates the depletion of all CD25+ 
T cells. Breast tumor growth of tumor-bearing mice treated with IL-2 immu-
notoxin was markedly inhibited (Knutson et al., 2006). Another approach for 
reducing intratumoral accumulation of Tregs is to block the function of the 
surface receptor CCR4. The specific expression of CCR4 on Tregs makes this 
chemokine receptor a promising target for anti-tumor therapy. Indeed, CCR4 
monoclonal antibody has the potential to inhibit tumor-directed Treg migra-
tion and thereby promote anti-tumor immunity (Ishida and Ueda, 2006). 
In humans, Treg depletion can be achieved by the FDA-approved fusion 
protein Ontak (denileukin diftitox). Ontak is the human equivalent to murine 
IL-2 immunotoxin. This protein is a toxin consisting of IL-2 fused to diphtheria 
toxin. Ontak binds to all CD25+ cells via IL-2. After receptor binding the protein 
is internalized, inhibits protein synthesis and thereby induces apoptosis in all 
CD25+ cells (Foss, 2000). In patients with renal cell carcinoma (RCC) Ontak 
significantly reduced blood Treg numbers and improved tumor-specific T cell 
activation (Dannull et al., 2005). However, a significant correlation of Treg 
depletion and tumor regression was not observed. This could be due to the 
fact that activated effector T cells up-regulate CD25 expression and thereby 
become susceptible for Ontak depletion. In conclusion the Ontak effective-
ness for tumor therapy is still uncertain. 
CTLA-4 blocking antibody is another approach for generating an effective 
anti-tumor immune response in human (Hodi et al., 2011). This antibody has a 
dual effect. On the one hand it inhibits Treg function and on the other hand it 
prevents inactivation of activated effector T cells. In patients with  metastatic 
melanoma anti-CTLA-4 antibody treatment reduced cancer progression. 
However, CTLA-4 blockade also induced potent autoimmune diseases such as 
dermatitis, hepatitis and hypophysitis (Phan et al., 2003). 
In contrast to anticancer therapy in mice, most therapies in humans show 
only slight effects for tumor regression and overall survival. Precise intratu-
moral Treg targeting is one of the major problems in boosting anti-tumor 
immunity in humans. In most approaches not only intratumoral Tregs are 
depleted, but also all other Tregs, which in turn evoke autoimmunity. 
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Another issue is the specificity of Treg targeting. Since precise human 
Treg markers are still missing, Treg depletion always involves the deple-
tion of other anti-tumor immunity promoting immune cells. In conclusion, 
new therapeutic approaches must be found. Beside total Treg depletion, 
preventing tumor infiltration of these cells appears to be a very prom-
ising therapeutic approach. In contrast to Treg depletion, blockade of 
Treg tumor infiltration would avoid side effects such as autoimmunity in 
treated cancer patients. 
1.2.4 Migration pattern of regulatory T cells
The trafficking of Tregs, as for all T cell subsets, is controlled by chemokines 
and chemokine receptors. The expression of chemokines and the appropriate 
chemokine receptors are tightly regulated. The chemokine receptor expres-
sion profile of immune cells is depending on the current cellular activation 
and differentiation stage (Lanzavecchia and Sallusto, 2000). The receptor 
profile of a certain immune cell determines whether it circulates through 
the secondary lymphoid tissue and blood cycle, encounters with antigen 
presenting cells (APCs), or migrates to sites of inflammation (Rossi and Zlotnik, 
2000; Zlotnik and Yoshie, 2000). 
Compared to other immune cells, murine and human Tregs express high 
levels of the chemokine receptors CCR4 and CCR8 (Iellem et al., 2001). The 
ligands of CCR4 are the macrophage-derived chemokine (MDC) CCL22 and 
the thymus and activation regulated chemokine (TARC) CCL17. CCL1, also a 
member of the CC chemokines, as well as the virokine vMIP-I are the  ligands 
for CCR8. Consistently with the chemokine receptor expression, Tregs show 
high chemotactic response to the chemokines CCL22, CCL17, CCL1 and  vMIP-I 
(Iellem et al., 2001). 
1.3 The chemokine CCL22
1.3.1 Molecular and biologic characteristics of CCL22
In general, all chemokines carry four cysteine motifs in conserved protein 
domains. These four cysteines are essential for the 3-dimensional protein 
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shape. The word chemokine is derived from chemotactic cytokines. The 
name chemokine indicates the function of these proteins which is mediating 
specific cell migration along a certain chemotactic gradient.
The chemokine CCL22 was first described in humans by Godiska and colleagues 
in 1997 (Godiska et al., 1997). One year later the murine equivalent was found 
by Schaniel and colleagues (Schaniel et al., 1998). Murine CCL22 shares 64% 
identity and 86% similarity with human CCL22 according to protein align 
analysis (www.ebi.ac.uk). The total length of murine CCL22 is 92 amino acids 
(aa) whereas human CCL22 consists of 93 amino acids. The first 24 N-terminal 
amino acids of murine and human CCL22 represent a signal peptide that 
mediates protein secretion after ribosomal translation. In the process of 
chemokine secretion this signal peptide is cleaved off the protein and mature 
CCL22 (69 aa long in human and 68 aa in murine) with a molecular mass of 
7.8 kDa is released (Godiska et al., 1997; Schaniel et al., 1998). Beside the full 
length CCL22 protein truncated forms can be found in mice and humans. 
The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) can remove 
two or four N-terminal peptides of CCL22. The shorter forms of CCL22 can no 
longer bind to CCR4, the exclusive receptor of CCL22. Thus, CCL22 cleavage 
mediates CCL22 inactivation which in turn could represent a feedback mecha-
nism of negative regulation (Proost et al., 1999). 
Initially, CCL22 was called macrophage-derived chemokine (MDC) because 
macrophages appeared to be the specific source of this chemokine. Beside 
macrophages CCL22 is expressed by monocyte-derived dendritic cells ( Godiska 
et al., 1997; Schaniel et al., 1998). Expression of murine and human CCL22 was 
observed mainly in the thymus, lymph nodes, lung and spleen (Godiska et al., 
1997; Schaniel et al., 1998; Tang et al., 1999). The highest chemotactic index 
among all T cells was observed for Tregs. The chemotactic index indicates 
the number of cells migrated in response to a certain chemokine divided by 
the number of spontaneously migrated cells. Thus, Tregs represent the major 
subset of immune cells that respond to CCL22 (Iellem et al., 2001).
The DC-specific expression of CCL22 is regulated by the DC activation status. 
Immature DCs express moderate CCL22 levels. However, after maturation the 
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expression of the chemokine is up-regulated (Sallusto et al., 1999). Iellem et al. 
postulated that this Treg specifi c chemokine could mediate Treg recruitment 
to APCs in order to prevent autoimmunity against self-antigens and inhibit 
overwhelming infl ammatory immune reactions against invading pathogens 
(Iellem et al., 2001). Since chemokines mediate the migration of T cells, Treg 
tumor infi ltration is also chemokine-dependent. The Treg specifi c chemokine 
CCL22 is an abundantly expressed chemokine in many human tumors such 
as breast cancer and ovarian carcinoma (Curiel et al., 2004; Gobert et al., 
2009; Ishida et al., 2006; Yang et al., 2006). Blockade of CCL22 prevents the 
migration of human Tregs into primary human ovarian tumors of nonobese 
diabetic/severe combined immunodefi ciency (NOD/SCID) mice (Curiel et al., 
2004). Thus, CCL22 seems to mediate Treg tumor infi ltration and thereby 
represents a promising target for anti-tumor immune therapy.
1.3.2 Characteristics of CCR4, the receptor of CCL22
Like all chemokine receptors, the CC chemokine receptor CCR4 is an integral 
protein and consists of seven helical trans-membrane domains (Figure 2). 
C-terminal
G protein
Extracellular
Plasma membrane
Intracellular
N-terminal
β
γ
α
Figure 2: Chemokine receptor structure. Chemokine receptors consist of seven trans-membrane 
domains that form three extracellular and three intracellular loops. The extracellular N-terminal end 
binds with high specifi city certain chemokines whereas the intracellular C-terminal end is G protein-
coupled and mediates signal transduction after ligand binding [Figure is adapted from an illustration 
published by Savarin-Vuaillat and Ransohoff, 2007]
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The helical receptor structure is achieved by three intracellular and three 
extracellular loops. The extracellular N-terminal end of the receptor protein 
determines chemokine binding specificity whereas the intracellular C-terminal 
end enables G protein binding and mediates signal transduction after ligand 
binding. In general, all chemokine receptors are very similar in size and bind 
chemokines with high selectivity (Power et al., 1995). 
Shortly after the identification of CCL22 as a new chemokine Imai and 
colleagues identified CCR4 as the exclusive receptor of CCL22 (Imai et al., 
1998). Beside CCL22, the chemokine CCL17 binds to CCR4. However, the 
binding affinity of CCL17 to CCR4 is 3-fold lower than the binding affinity of 
CCL22 (Imai et al., 1998). CCR4 is specifically expressed by Tregs. Consistent 
with these data the highest chemotactic response towards CCL22 as well as 
CCL17 among all leukocytes was observed for Tregs (Iellem et al., 2001).
1.4 Toll-like receptors
Toll-like receptors (TLRs) play a crucial role in the activation of the innate and 
adaptive immune system. TLRs belong to the receptor superfamily of pattern 
recognition receptors (PRRs). These receptors recognize highly conserved 
 molecules derived from invading pathogens, also known as pathogen-asso-
ciated molecular pattern (PAMPs). PAMPs are essential for pathogen survival 
and function. Thus, PAMPs are highly conserved, and pathogens with muta-
tions in these molecular structures are usually not viable, making PAMPs 
an ideal target for pathogen recognition. Another subfamily of the PRR 
 superfamily is represented by the RIG-I-like receptors (RLR). Intracellularly 
expressed retinoic-acid-inducible gene I (RIG-I) and melanoma-differentia-
tion-associated gene 5 (MDA-5) are receptors of this family.
The TLR family was identified in 1997 due to their sequence similarities with 
the Drosophila melanogaster receptor protein Toll (Medzhitov et al., 1997). 
After antigen encounter the Drosophila Toll receptor activates the produc-
tion of antimicrobial proteins. Mutations of this protein lead to high suscep-
tibility to fungi and Gram-positive bacteria (Lemaitre et al., 1996). In most 
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vertebrates ten to twelve functional TLRs can be found (Roach et al., 2005). 
 
1.4.1 Toll-like receptors and their ligands
In human at least ten functional TLRs (TLR1 to 10) are expressed. TLR1 to TLR9 
are conserved between humans and mice although murine TLR8 and TLR10 
are not functional. Additionally, mice express TLR11, 12 and 13 which are 
mis sing in humans (Akira et al., 2006). The receptors TLR1, 2, 4, 5, 6, 10 and 
11 are located on the cell surface of immune cells such as macrophages and 
dendritic cells. Due to their location these receptors recognize extracellular 
PAMPs from microbial membranes such as the endotoxin lipopolysaccharide 
(LPS) or lipoproteins and lipids from fungal cell walls. 
TLR PAMP Pathogen Synthetic ligand Location
TLR1 Dimers with TLR2 extracellular
TLR2 Triacyl lipopeptides
Diacyl lipopeptides
Zymosan
Bacteria
Mycoplasma
Fungus
n.d. extracellular
TLR3 dsRNA Virus poly (I:C); poly (A:U) intracellular
TLR4 LPS
Envelope proteins
Bacteria
Virus
monophosphoryl 
lipid A
extracellular
TLR5 Flagellin Bacteria n.d. extracellular
TLR6 Dimers with TLR2 extracellular
TLR7 ssRNA, siRNA RNA virus adenosine and gua-
nosine derivative
intracellular
TLR8 ssRNA RNA virus adenosine and gua-
nosine derivative
intracellular
TLR9 CpG
DNA
Malaria hemozoin
Bacteria
DNA virus
Parasites
unmethylated 
CpG motifs
intracellular
TLR10 n.d. n.d. extracellular
TLR11 Profilin-like molecule Parasites n.d. extracellular
TLR12 n.d. n.d. n.d.
TLR13 n.d. n.d. n.d.
Table 1: Overview of all known physiologic and synthetic TLR ligands as well as cellular TLR 
locations. TLR 11, 12 and 13 is missing in humans, whereas TLR9 and TLR10 are not functional in 
mice (n.d. indicates none described). References: Alexopoulou et al., 2001; Coban et al., 2005; 
Hayashi et al., 2001; Heil et al., 2004; Hemmi et al., 2002; Kurt-Jones et al., 2000; Lund et al., 
2003; Ozinsky et al., 2000; Poltorak et al., 1998; Takeuchi et al., 1999; Yarovinsky et al., 2005.
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In contrast to the surface TLRs the receptors TLR3, 7, 8 and 9 are located intra-
cellularly in endosomal and lysosomal vesicles as well as in the membrane 
of the endoplasmatic reticulum (Roach et al., 2005). The intracellular TLRs 
recognize nucleic acids such as bacterial unmethylated CpG motifs or viral 
single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) (Akira et al., 
2006). In table 1 natural occurring and synthetic TLR ligands as well as cellular 
TLR locations are summarized. 
1.4.2 Immune activation by Toll-like receptor ligands
After a pathogen invasion for example during bacterial infection, pathogen 
specific molecules (PAMPs) are recognized by TLRs. Ligand binding leads to 
TLR activation and thereby induces patterns of gene expression which in turn 
activate the hosts innate immune system and subsequently instructs the rise 
of an antigen specific immune reaction mediated by the adaptive immune 
system. TLR ligand binding is the first step of this signal cascade. This binding 
causes conformational changes of the receptors and dimerization with 
other activated TLRs. Thereby, adaptor proteins such as myeloid differentia-
tion primary response gene 88 (MyD88) which are crucial for signal trans-
duction are recruited. All TLRs except TLR3 utilize MyD88 for intracellular 
signal transduction. Beside MyD88 three other adaptor proteins are used for 
TLR signal transduction, the TIR-containing adapter inducing IFN-β (TRIF), 
the TRIF-related adapter molecule (TRAM) and the TIR domain-containing 
adapter molecule (TIRAP) (Kawai and Akira, 2007; Gay et al., 2006). Signal 
transduction via these adaptor proteins leads to the activation of mitogen-
activated protein (MAP) kinase complex and nuclear factor-кB (NF-кB). The 
transcription factor NF-кB in turn activates the transcription of a variety of 
pro-inflammatory cytokines such as IL-1, IL-6, IL-10 and IL-12 as well as tumor 
necrosis factor alpha (TNF-α) (Meylan et al., 2006; Moynagh, 2006). 
In addition to the MAP kinase and NF-кB signal pathway, intracellular TLRs 
can utilize a second discrete pathway for signal transduction. In this pathway 
adaptor protein recruitment leads ultimately to IFN regulatory factor (IRF) 
activation such as IRF-3, IRF-5 and IRF-7 which in turn induces type I IFN 
production (Figure 3). The IRF pathway is primarily induced after viral infec-
tion (Doyle et al., 2002; Schoenemeyer et al., 2005).
16
Introduction
TLR 4
NF-κB
IRFs
M
yD
88
TI
RA
P
M
yD
88
TI
RA
P
TR
A
M
TR
IF
TR
IF
TLR 2 TLR 1/6
Lipoproteins
M
yD
88
MyD88
TLR 5
TLR7/8 or 9
TLR3
RIG-I or 
MDA5
dsRNA
LPS Flagellin
Adapter proteins
Endosome
Plasma membrane
Cytoplasm
ssRNA or DNA
Pro-inammatory cytokines Type I Interferons
Figure 3: Schematic diagram of pattern-recognition receptors. The diagram shows the toll-like 
receptor and RIG-I-like receptor family. Examples of receptor ligands, cellular receptor localization, 
adapter proteins and relevant transcription factor are illustrated. Selected relevant references can be 
found in the text [Figure is based on an review of Kanzler et al., 2007].
The amount and type of secreted mediators after TLR activation determine 
the type and magnitude of the subsequent immune reaction. This in turn 
is dependent on the type and amount of invading pathogen as well as the 
cell type that is activated by a certain pathogen. Secreted cytokines such as 
IL-1, IL-6, IL-10 and IL-12 recruit other innate immune cells such as neutro-
phils and macrophages to the site of infl ammation in order to potentiate 
an ongoing immune response. In addition, TLR activation is a crucial step in 
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the activation of the adaptive immune system. For instance, immature DCs 
that recognize pathogens by TLRs start to maturate, produce co-stimulatory 
molecules such as CD80/86 and migrate to the lymph nodes where they 
initiate an antigen specific adaptive immune reaction by activating T cells 
(Shortman and Heath, 2001).
1.4.3 Toll-like receptor ligands and anti-cancer immunotherapy
Manipulating the innate immune system could affect the progress of many 
diseases. Several different TLR ligands show promising effects for the treat-
ment of certain diseases and are used in the clinic already. TLR ligands are 
utilized for cancer, allergy and viral infection treatments. By the use of 
synthetic TLR ligands the innate immune system can be activated and a 
tumor-induced immune suppression can be abolished (Kanzler et al., 2007). 
Treating tumor-bearing mice with the TLR9 ligand CpG reduced tumor growth 
and increased overall survival (Heckelsmiller et al., 2002; Houot and Levy, 
2009; Krieg, 2008). Currently, the anti-tumoral effects of CpG in humans are 
tested in clinical trials (Weber et al., 2009; Vollmer and Krieg et al., 2009). 
The synthetic TLR7 agonist imiquimod is another example for effective 
TLR-mediated anti-cancer therapy. This TLR ligand is FDA approved and used 
in the clinic to treat superficial basal cell carcinoma and vulvar intraepithelial 
neoplasia (Chang et al., 2005; van Seters et al., 2008). In addition to TLRs 
other PRR members represent promising targets for anti-tumor therapy. For 
instance, the synthetic small RNA molecules poly (I:C) and triphosphate RNA 
activate the intracellular receptors MDA-5 and RIG-I, respectively (Gitlin et 
al., 2006; Anz et al., 2009). In tumor-bearing mice these ligands could block 
tumor development and increase overall survival (Tormo et al., 2006; Poeck 
et al., 2008). 
In addition, there is an increasing interest in using TLR ligands as adjuvants for 
existing anti-tumor therapies such as radiation, anti-tumor antigen directed 
monoclonal antibodies or cytotoxic drugs (Kanzler et al., 2007). In tumor-
bearing mice CpG could be used as an adjuvant for boosting the efficiency of 
anti-cancer vaccines (Heckelsmiller et al., 2002; Bourquin et al., 2005; Tormo et 
al., 2006; Speiser et al., 2005). In human clinical trials for using PRR agonists in 
combination with anti-cancer vaccines are under way. 
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The mechanisms by which PRR agonists promote anticancer immunity are 
complex. Activation of the adaptive immune system subsequent of innate 
immune system activation is a very important step for inducing an efficient 
anti-tumor immune reaction by PRR ligands. For instance, PRR ligands can 
cause DC maturation. Mature DCs express co-stimulatory molecules. Thereby, 
these DCs can activate CD8+ cytotoxic T cells which in turn can generate a 
potent anti-tumor immune reaction (Haring et al., 2006). Especially TLR7 
and TLR9 activation induces high levels of IFN-α produced by plasmacytoid 
dendritic cells (pDCs). IFN-α in turn initiates MHC-I expression on tumor cells 
and thereby enhances detection and killing of these cells by activated cytotoxic 
T cells (Marley et al., 1989). In addition to cytotoxic T cells natural killer cells 
seem to play an important role for PRR ligand-induced anti-tumor immunity 
(Berger et al., 2009; Bourquin et al., 2009; Sivori et al., 2004). Nevertheless, 
the precise mechanisms of PRR agonist-mediated immunotherapy are still 
unknown. In particular the role of Tregs in this therapeutic setting is rarely 
investigated. Although it is reported that ligands for TLRs and RLRs abrogate 
the suppressive function of Tregs (van Maren et al., 2008; Anz et al., 2009), 
little is known about their precise effect on Tregs in tumor-bearing mice and 
humans. Moreover, it remains unclear how TLR and RLR ligands influence 
Treg tumor infiltration. 
1.5 Objectives
During tumor development an immunosuppressive milieu is created by the 
tumor which prevents an efficient anti-tumor immune reaction. In the last 
decade the functions of Tregs were described in great detail, and Tregs were 
identified in several human tumors as one of the key mediators of this tumor-
induced immune suppressive environment. In contrast to Treg function the 
knowledge of the mechanisms that recruit Tregs into the tumor tissue in 
order to mediate intratumoral immune suppression is still very limited.
In general, the migration of immune cells is mediated by chemokines. Thus, 
intratumoral Treg recruitment is presumably mediated by the increased 
expression of one or more chemokines. One very promising candidate is the 
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chemokine CCL22. This chemokine is a potent Treg attractor (Iellem et al., 
2001) and is highly expressed in many tumors (Curiel et al., 2004; Gobert et 
al., 2009; Ishida et al., 2006; Yang et al., 2006). From a therapeutic perspective, 
identifying the mechanisms that mediate Treg recruitment to the tumor tissue 
represents an attractive tool for manipulating the tumor-induced immune 
suppressive milieu. Previous experiments in our group have shown that TLR 
stimulation reduces the amount of intratumoral CCL22 and the number of 
Tregs in the tumor tissue. Since TLR ligands can induce tumor regression, 
CCL22 suppression could be an important part of this TLR ligand-mediated 
anti-tumor immune reaction. 
Since little is known about the impact of intratumoral CCL22 on tumor-induced 
Treg recruitment, tumor development, disease outcome and TLR ligand-
induced tumor therapy, this work was designed to answer the following 
questions:
u Which cell type produces CCL22 in the tumor tissue?
v What is the impact of intratumoral CCL22 on tumor growth and overall 
 survival?
w What is the mechanism of TLR ligand-mediated intratumoral CCL22 
 suppression? 
x Is TLR ligand-mediated intratumoral CCL22 suppression important for 
 the TLR ligand-induced anti-tumor immune reaction?
The answer to these questions should allow a better understanding of the 
mechanisms of tumor development and growth. Thereby, promising novel 
targets for an efficient anti-cancer therapy may identified. 

Materials
&
Methods
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2. Materials & Methods
2.1 Materials
2.1.1 Technical equipment
Alpha Imager      Alpha Innotech, San Leandro, USA
Balance (LP 6209)      Sartorius, Göttingen, Germany
Cell culture CO2 incubator (BD 6220)   Heraeus, Hanau, Germany
Cell culture laminar flows    Heraeus, Hanau, Germany
Centrifuge 5424      Eppendorf, Hamburg, Germany
FACS Canto II     BD bioscience, Heidelberg, Germany
Gel electrophoresis systems    Bio-rad, Munich, Germany
LightCycler 2.0 System    Roche, Mannheim, Germany
MiniMACS, QuadroMACS    Miltenyi Biotec, Bergisch Gladbach,  
       Germany
Mithras LB940 multilabel plate reader   Berthold Technologies, Bad Wildbad,  
       Germany
Multifuge 3L-R      Heraeus, Hanau, Germany
Nanodrop ND-1000     NanoDrop, Wilmington, USA
Neubauer hemocytometer    Optik Labor Frischknecht, Balgach,  
       Germany
pH meter       WTW, Weilheim, Germany
Power Supply 200/2.0     Bio-Rad, Munich, Germany
Refrigerators (4°C, -20°C)     Bosch, Gerlingen, Germany
Refrigerators (-80°C)     Thermo Scientific, Waltham , USA
Shaker       NeoLab, Heidelberg, Germany
Thermocycler T3      Biometra, Göttingen, Germany
Thermomixer      Eppendorf, Hamburg, Germany
Vortex       VF2 Janke & Kunkel, Staufen, Germany
2.1.2 Chemicals, reagents and buffers
Agarose LE       Biozym, Hess Oldendorf, Germany
Bovine serum albumine (BSA)    Sigma Aldrich, Steinheim, Germany
Chloroform       Sigma Aldrich, Steinheim, Germany
Collagenase      Sigma Aldrich, Steinheim, Germany
Dimethyl sulfoxide (DMSO)    Sigma Aldrich, Steinheim, Germany
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DNase I       Sigma Aldrich, Steinheim, Germany
dNTP Mix, 10 mM     invitrogen, Carlsbad, USA
Donkey Serum     Millipore, Billerica, USA
Dulbecco’s Phosphate buffered saline (PBS)  PAA, Pasching, Germany
Ethanol      Sigma Aldrich, Steinheim, Germany
Ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, Steinheim, Germany
FACSFlow, FACSClean, FACSShutdown  BD bioscience, Heidelberg, Germany
Isoflurane (Forene®)     Abbott, Zug, Switzerland
Isopropanol (100 Vol%)    Sigma Aldrich, Steinheim, Germany
Isopropanol (70 Vol%)     Apotheke Innenstadt, LMU Munich
Lipofectamine™ 2000 Transfection Reagent invitrogen, Carlsbad, USA
MgCl2 25mM     Fermentas, St. Leon-Rot, Germany
MolTaq DNA Polymerase    Molzym, Bremen, Germany
O’GeneRuler™ DNA Ladder Mix   Fermentas, St. Leon-Rot, Germany
Percoll, d=1,124 g/ml    Biochrome, Berlin, Germany
Pfu Ultra Fusion HS     Stratagene, Waldbronn, Germany
Sodium pyruvate      PAA, Pasching, Austria
Trizol reagent      invitrogen, Carlsbad, USA
Trypan blue       Sigma Aldrich, Steinheim, Germany
Trypsin (10x)      PAA, Pasching, Austria
Tween 20       Roth, Karlsruhe, Germany
MACS buffer      Fixation buffer for FACS samples
2 mM EDTA       2% PFA
2% FCS in PBS     in PBS
ELISA assay diluent     ELISA wash buffer
1% BSA      0.05% Tween 20
in PBS, pH 7.0     in PBS
2.1.3 Cell culture reagents, media and cytokines
2-Mercaptoethanol     Sigma-Aldrich, Steinheim, Germany
Dulbecco’s modified Eagle´s medium   PAA, Pasching, Austria
(DMEM), high glucose
Fetal calf serum (FCS)     GibcoBRL, Karlsruhe, Germany
L-glutamine 200mM     PAA, Pasching, Austria
MEM-NEAA (non-essential amino acids)  GibcoBRL, Karlsruhe, Germany
Roswell Park Memorial Institute (RPMI)  PAA, Pasching, Austria
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1640 medium
Penicillin/Streptomycin (100x)    PAA, Pasching, Austria
VLE RPMI 1640 medium (very low endotoxin) Biochrom, Berlin, Germany
4T1 medium      B16, CT26, Panc02 medium
10% FCS       10% FCS
2 mM L-glutamine      2 mM L-glutamine  
100 IU/ml penicillin     100 IU/ml penicillin
100 μg/ml streptomycin     100 μg/ml streptomycin
in RPMI       in DMEM
Meth-A medium      mGC8, DC2.4 medium
10% FCS       10% FCS
2 mM L-glutamine      2 mM L-glutamine  
100 IU/ml penicillin     100 IU/ml penicillin
100 μg/ml streptomycin     100 μg/ml streptomycin
2 mM sodium pyruvate    2 mM sodium pyruvate
2 mM nonessential amino acids   2 mM nonessential amino acids
in RPMI       in DMEM    
  
T cell and DC medium    Cryo medium
10% FCS      50% appropriate culture medium
2 mM L-glutamine     40% FCS
100 IU/ml penicillin     10% DMSO
100 μg/ml streptomycin
2 mM sodium pyruvate
2 mM nonessential amino acids
0.0001% of 2-mercaptoethanol
in RPMI 1640
Cytokines and growth factors
Granulocyte-macrophage colony- PeproTech, Hamburg, Germany
stimulating factor (GM-CSF) 
IFN-α, mouse recombinant   R&D Systems, Wiesbaden, Germany
IFN-γ, mouse recombinant   R&D Systems, Wiesbaden, Germany
Interleukin-1b, mouse recombinant  PeproTech, Hamburg, Germany
Interleukin-2, mouse recombinant  PeproTech, Hamburg, Germany
Interleukin-4, mouse recombinant  PeproTech, Hamburg, Germany
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Interleukin-6, mouse recombinant  PeproTech, Hamburg, Germany
Interleukin-10, mouse recombinant  PeproTech, Hamburg, Germany
Interleukin-12, mouse recombinant  PeproTech, Hamburg, Germany
Disposable plastic materials for cell culture experiments were purchased from 
Corning (Corning, USA), Eppendorf (Hamburg, Germany), Falcon (Heidelberg, 
Germany), Greiner (Frickenhausen, Germany) or Sarstedt (Nümbrecht, 
Germany).
2.1.4 Toll-like receptor ligands
CpG 1826 (CpG)      Coley, Massachusetts, USA
5’-TCCATGACGTTCCTGACGTT-3’
poly (I:C)       Amersham Bioscience, Little 
        Chalfont, UK
2.1.5 Kits
Bio-Plex Cell Lysis Kit    Bio-Rad, Munich, Germany
Cell proliferation ELISA, BrdU    Roche, Mannheim, Germany
CCL22 murine Cytokine ELISA sets   BD Bioscences, San Diego, USA
CD11c MicroBeads MACS cell separation Miltenyi Biotec, 
       Bergisch Gladbach, Germany
CD4+CD25+ Regulatory T Cell Isolation Kit  Miltenyi Biotec, 
       Bergisch Gladbach, Germany
CD4 Micro Beads MACS cell separation   Miltenyi Biotec, 
       Bergisch Gladbach, Germay
FOXP3 Staining Buffer Set    eBioscience, San Diego, USA
GeneJET™ Plasmid Miniprep Kit 50 preps Fermentas, St. Leon-Rot, Germany
JetQuick Gel Spin Kit    Genomed, Löhne, Germany
JetQuick PCR Purification Kit   Genomed, Löhne, Germany
Spin Universal RNA Mini Kit   Invitek, Berlin, Munich
Revert Aid First strand cDNA Synthesis Kit Fermentas, St. Leon-Rot, Germany
Light Cycler 4800 Probes Master   Roche, Mannheim, Germany 
LS, MS and LD columns     Miltenyi Biotec, 
       Bergisch Gladbach, Germany
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2.1.6 FACS antibodies 
Description     Isotype   Clone  Company
B220 Pacific Blue a-mouse Rat IgG2a,κ	 	 RA3-6B2 BioLegend
CD3κ	FITC a-mouse	   Ar Ham IgG  145-2C11 BioLegend
CD4 APC/Cy7 a-mouse  Rat IgG2b,κ  GK1.5   BioLegend
CD8a PerCp a-mouse  Rat IgG2a,κ	  53-6.7  BioLegend
CD11b PE a-mouse   Rat IgG2b  M1/70.15 ImmunoTools
CD11c APC a-mouse  Ar Ham IgG  N418   BioLegend
CD25 PerCp a-mouse  Rat IgG1,κ	  PC61   BioLegend
CD49b FITC a-mouse  Rat IgM,κ  DX5  BioLegend
FOXP3 eFlur®450 a-mouse  IgG2a,κ  FJK-16s eBioscience
GR1 APC/Cy7 a-mouse  Rat IgG2b,κ	 	 RB6-8C5 BioLegend
2.1.7 Software
Adobe Creative Suite     Adobe Systems, San José, USA
BD FACSDiva      BD Biosciences, San Diego, USA
FlowJo       Tree Star, Ashland, USA
GraphPad      GraphPad Software, 
       Inc., California, USA
Microsoft Office      Microsoft, Redmond, USA
2.2 Molecular biology methods
2.2.1 Polymerase chain reaction
The polymerase chain reaction (PCR) is a method to amplify a defined part 
of an extracted DNA sample. To define this part, two specific primers are 
needed that flank the region of interest, one upstream and one downstream 
primer. The general range of a primer is 15-30 bases, and the guanosine and 
cytosine amount should be 40-60%. The maximum size of the DNA fragment, 
which can be amplified with a standard PCR, is 10.000 bases. A PCR consists 
of several cycles. After each cycle the amount of amplified DNA is doubled.
The PCR method was used for the amplification of specific cDNA fragments 
or genomic DNA. If a PCR product was used for cloning, the PCR primers 
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were designed to introduce restriction endonuclease recognition sites to 
facilitate specific cloning into a certain target plasmid. For this purpose 
it was vital to prevent point mutations. Thus, the polymerase  PfuUltra 
(Fermentas) was used. This enzyme has a 3’ to 5’ exonuclease activity 
and thereby provides a higher fidelity than normal polymerases. For pure 
analytical purposes it was sufficient to use Moltaq (Molzym) polymerase 
which lacks proofreading activity. The composition of a standard PCR reac-
tion mix for both polymerases is shown below:
PfuUltra Polymerase        
as required    DNA (100 pg to 500 pg)
1x     10x PfuUltra II Reaction Buffer
0.2 mM each dNTP   invitrogen™ dNTP Mix (10 mM each dNTP)
0.25 μM    upstream primer (10 μM)  
0.25 μM    downstream primer (10 μM)
1.25 U     PfuUltra DNA Polymerase (5 U/μl)
Moltaq Polymerase        
as required    DNA (100 pg to 500 pg)
1x     10x Moltaq Reaction Buffer
10%     PCR Enhancer Solution
1mM     MgCl2 (25mM)
0.2 mM each dNTP   dNTP Mix (10 mM each dNTP)
0.25 μM    upstream primer (10 μM)  
0.25 μM    downstream primer (10 μM)
1 U     Moltaq DNA Polymerase (5 U/μl)
Standard PCR cycling conditions:
Function    Duration Temperature  
Initial DNA Denaturation  5 minutes  95°C
DNA Denaturation   20 s  95°C
Primer Annealing   20 s  65°C     30 cycles
Primer Extension   15 s  72°C
Final Extension   3 minutes 72°C
End     ∞	 	 4°C
After PCR reaction 1x DNA loading dye (Fermentas) was added to each sample. 
It contains two different dyes (bromophenol blue and xylene cyanol FF) for 
visual tracking of DNA migration during electrophoresis. Samples mixed with 
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loading dye were loaded on an agarose gel for length separation by gel elec-
trophoresis (see below).
2.2.2 Polymerase chain reaction purification
If PCR products were needed for further experiments, such as molecular cloning, 
PCR products were purified by JETQuick PCR Purification Kit. Purification was 
done according to manufacturer’s protocol. In brief: 400 μl of solution H1 
were added to each sample and pipetted into a JetQuick spin column. After 
centrifugation at 12,000 g for 1 minute the flow-through was discarded and 
the column washed with 500 μl H2 solution. The column was washed twice by 
centrifugation at 12,000 g for 1 minute, and the flow-through was discarded. 
For DNA elution 40 μl pre-warmed (65-70°C) water was added to the center of 
the column followed by a final centrifugation step at 12,000 g for 2 minutes.
2.2.3 Gel electrophoresis
Gel electrophoresis is a technique to separate and visualize DNA fragments of 
different sizes. This technique was used to analyze PCR samples. For the elec-
trophoresis a 2% agarose gel (2% agarose; 1x TAE) was used. After boiling 
the gel, 0.003% ethidium bromide was added, and the gel was poured. While 
cooling down, the gel forms a crosslinked polymer. This polymer allows the 
separation of DNA fragments due to their size. DNA is negatively charged. 
Thus, the DNA moves in an electric field from the negative pole to the posi-
tive pole. The smaller a DNA fragment, the faster it moves through the gel. 
Hence, DNA fragments of different sizes are separated. For size determination 
of the separated PCR fragments a 1 kb DNA Ladder (Fermentas - GeneRuler™ 
) was used.
2.2.4 DNA gel extraction
The JETQuick Gel Extraction Kit was used for double-stranded DNA fragment 
purification of PCR samples after gel electrophoresis. The kit purifies DNA 
fragments of a length of 40 bp up to 20 kb. 80-95% of the fragments are 
recovered with a maximal binding capacity of 20 μg. The DNA adsorbs to 
the silica-membrane of the JETQuick spin column in high-salt buffer while 
contaminants pass through the column. The DNA is eluted in low-salt buffer 
(Vogelstein and Gillespie, 1979).
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JETQuick Gel Extraction was done according to manufacturer’s protocol. In 
brief: The appropriate DNA band was excised from an agarose gel after gel 
electrophoresis and transferred into an suitable tube. For each 100 mg gel 
slice 300 μl solution L1 was added. To solubilize the gel, the tube was incu-
bated at 50°C for 15 minutes. Then the solubilized gel was loaded into a 
JETQuick spin column and centrifuged at 12,000 g for 1 minute. The flow-
through was discarded and the column washed by adding 500 μl of recon-
stituted solution L2. Followed by another centrifugation step (12,000 g for 1 
minute) the flow-through was discarded again. Finally, the column bond DNA 
was eluted by adding 50 μl of sterile water onto the center of the silica matrix 
of the JETQuick spin column and centrifugation at 12,000 g for 2 minutes. 
Higher DNA concentration was obtained by using preheated water (65-75°C) 
as elution buffer.
2.2.5 Molecular cloning
Molecular Cloning is a technique to integrate a specific sequence into a certain 
vector for amplification in bacteria. In order to amplify the vector and the 
integrated sequence, the cloning vector must carry an origin of replication. 
Additionally, one or more antibiotic resistances are needed for selection. In 
general, each cloning involves four steps: fragmentation (digest), ligation, 
transformation and selection.
Restriction digests
For analytical purposes 0.2-2 μg of DNA were digested with 10-20 U of one or 
two restriction endonucleases in an appropriate 1× buffer. Restriction digests 
were carried out for 1 hour at 37ºC. After digestion samples were separated 
by gel electrophoresis and extracted via gel extraction kit (see section 2.2.3) 
or directly purified by JETQuick PCR Purification Kit (see section 2.2.2). DNA 
amounts were measured by standard photometry.
Ligation
To insert a specific DNA fragment (insert) into a multiple cloning site (MCS) 
of a plasmid vector, both, the insert and the vector, were digested with one 
or two appropriate restriction endonucleases (see above). After digest and 
fragment purification the gained insert and vector were used for ligation. 
30
Materials & Methods
An insert vector ratio of 3 to 1 was used. Calculation of required insert and 
vector amounts for ligation was done according following formula:
  a: amount of vector (ng)
  b: size of vector (bp)
  c: size of insert (bp)
  d: amount of insert (ng)
Ligation was performed with a T4 DNA Ligase (Fermentas) and 1x Ligation 
buffer in a total volume of 20 μl at 17°C overnight. Ligation efficiency was 
verified by bacteria transformation with 10 μl ligation product and subse-
quent antibiotic selection. To verify proper integration and correct orienta-
tion of the insert, control PCRs with appropriate primers were performed 
after positive clone amplification and subsequent vector purification by 
plasmid DNA purification (see below). Additionally, in some cases positive 
clones were analyzed by sequencing (done by mwg/operon).
Transformation
For transformation chemically competent DH5κ E.coli. were used. After 
thawing the competent cells on ice, plasmid vector was added to the cells. 
Followed by heat shock at 42°C for 1 minute the cells were placed back on ice. 
Finally, the cells were plated out on LB-agarose plates. For positive cell selec-
tion LB-plates with an appropriate antibiotic in a concentration of 1:1000 
were used (usually ampicillin). If transformation was successful, colonies were 
observed after incubating the plates at 37°C for 24 hours.
2.2.6 Plasmid miniprep
Plasmid DNA purification from bacteria was done with the GenJET™ Plasmid 
Miniprep Kit. The procedure is based on alkaline lysis of bacterial cells followed 
by adsorption of DNA onto silica in the present of high salt (Vogelstein and 
Gillespie, 1979). The GenJET™ columns contain a silica membrane that enables 
a selective absorption of plasmid DNA in high-salt buffer and an elution of 
plasmid DNA in low-salt buffer. This ensures that only DNA will be isolated 
while RNA, cellular proteins, and metabolites are discarded.
The kit guarantees a DNA recovery of 90-95% with an maximum DNA yield 
a c d=x x
b
3
1
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of 50 μg. For Plasmid DNA miniprep bacteria were amplified on an antibi-
otic-containing LB-plate, positive clones picked and proliferated in 2 ml anti-
biotic containing LB-medium for 16 hours at 37°C. Bacteria were harvested 
by centrifugation at 12,000 g for 2 minutes. The pelleted cells were resus-
pended in 250 μl Resuspension Solution, and 250 μl Lysis Solution was added. 
After thoroughly mixing the solution by inverting the reaction tube, 350 μl 
Neutralization Solution was added. For pelleting cell debris and chromosomal 
DNA, centrifugation at 12,000 g for 5 minutes was performed. The obtained 
supernatant was loaded on a GeneJET™ spin column. After another centrifu-
gation step at 12,000 g for 1 minute the flow-through was discarded and the 
column washed two-times with 500 μl Wash Solution. Each wash step was 
followed by centrifugation at 12,000 g for 1 minute. To remove residual wash 
solution, an additional centrifugation step (12,000 g, 1 minute) was performed 
before DNA was eluted by adding 50 μl pre-warmed water (70°C) to the center 
of the spin column and centrifuging the tube for 2 minutes at 12,000 g.
2.2.7 Genomic DNA isolation
Genomic DNA was extracted from small tissue pieces cut from the tip of the 
tail of five week old mice. The tissue was lysated at 56°C in 500 μl Laird’s Buffer 
(200 mM NaCl, 100 mM Tris-HCl pH 8.3, 5 mM EDTA, 0.2% sodium dodecyl 
sulfate) containing 0.15 mg/ml proteinase K. After 24 hours the samples were 
centrifuged at 14.000 rpm for 5 minutes. The supernatants were mixed with 
the same volume of isopropanol. Through inverting 3-4 times DNA appeared 
as small white fibres. Finally, the samples were centrifuged again, the isopro-
panol was completely removed and the DNA dissolved in 100 μl water. The 
DNA was used for genotyping by PCR. Therefore, 1 μl of each lysate was used 
for a standard PCR (see methods 2.2.1). Primarily, the quality and quantity 
of DNA in each sample was verified with two primers that detect a common 
gene. In the case of a positive result a second PCR was performed to screen 
for the desired transgene. For further analyses samples were stored at 4°C.
2.2.8 Generation of a Tet-On CCL22 expression construct
For the generation of an inducible CCL22 expression vector a Tet-On Gene 
Expression construct was used (HT1080 Cell Line & pTRE2 Vector, 1999). This 
construct enables the doxycycline-dependent expression of CCL22. It consists 
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of two elements. The fi rst element is the activator rtTA. The expression of this 
activator is regulated by the cytomegalovirus promoter CMV. This promoter 
guarantees a strong constitutive expression of rtTA in all cells carrying the 
Tet-On Gene Expression construct. The second element contains the tet 
promoter that regulates the expression of CCL22. The whole system is doxycy-
cline sensitive. Doxycycline is a member of the tetracycline antibiotics group. 
In the absence of doxycycline the activator rtTA cannot bind to the promoter 
tet. Thus, tet is silent, and the gene of interest is not expressed. In the pres-
ence of doxycycline the antibiotic binds to rtTA. That leads to a conforma-
tion change of rtTA and enables rtTA to bind to the promoter tet. Thereby, 
the promoter is activated and promotes the expression of CCL22 (Figure 4). 
After integrating CCL22 into the Tet-On Gene Expression construct, the newly 
generated rtTA-Tet-CCL22 construct was inserted into the genome of CT26 
mouse tumor cells via lentiviral transduction. 
rtTA tet CCL22CMV Promoter
tet CCL22 tet CCL22
rtTACMV Promoter rtTACMV Promoter
DoxDox
CCL22rtTA
Figure 4: Doxycycline-dependent expression of CCL22. The construct consists of two elements. 
First, the constitutive promoter CMV that guarantees a strong expression of the activator rtTA. Second, 
the rtTA controlled tet promoter that regulates the expression of the gene of interest (CCL22). In the 
absence of doxycycline rtTA cannot activate the promoter tet. In the presence of doxycycline rtTA 
binds doxycycline. The conformation of rtTA changes. Thus, rtTA is able to bind to and thereby acti-
vate the promoter tet, that in turn promotes the expression of CCL22.
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2.2.9 Lentiviral tumor cell transduction
To guarantee stable genomic integration of the rtTA-Tet-CCL22 construct 
(containing a puromycin selection marker) into the target cell, lentiviral 
transduction was used. Therefore, the transgene was packed into a lentivirus 
envelope. 
The recombinant lentivirus was produced by transient transfection of HEK 
293T cells using GeneJuice Transfection Reagent (Novagen). HEK 293T cells 
were transfected with a viral construct (containing rtTA under the control of 
a CMV promoter and CCL22 mRNA downstream of a Tet-responsive promoter, 
FugW backbone), VSV-G and delta 8.9 in a ratio of 10:1:10. Infectious lenti-
viruses were harvested at 72 hours post-transfection and filtered through a 
low-protein binding 0.45 μm filter flask. The filtered recombinant lentiviruses 
were packed on 20% sucrose solution and concentrated by ultracentrifuga-
tion (2 hours at 27,000 rpm). Subsequently, virus pellet was dissolved and used 
for CT26 cell transduction. 36 hours post-transduction cells were selected by 
puromycin (5 μg/ml) treatment for 72 hours. After 24 hours incubation with 2 
μg/ml doxycycline inducible CCL22 expression of these novel generated puro-
mycin selected rtTA-CCL22-CT26 cell lines were verified by ELISA. 
2.2.10 RNA isolation
Single cell suspension RNA isolation
Total RNA was extracted from tumor-infiltrating immune cells and cultured 
cells with Trizol reagent. 0.5 to 2.0 x 106 cells per well of a 96 well plate were 
used for Trizol RNA isolation. All subsequently indicated volumes are opti-
mized for lysing cells in a 96 well format. Initially, cells were lysed directly in a 
culture dish by adding 100 μl/well Trizol. After 5 minutes incubation at room 
temperature cell lysates were transferred into a 1,5 ml Eppendorf tube, and 
20 μl chloroform was added per sample. Next, samples were mixed by hand, 
incubated for 5 minutes at room temperature and centrifuged at 12,000 g for 
15 minutes at 4°C. After centrifugation the mixture separated into a lower 
red, phenol-chloroform phase, an interphase and a colorless upper phase that 
contained the extracted RNA. The upper phase of each sample was trans-
ferred into a new tube, and RNA was precipitated by adding 0.1 ml isopropyl 
alcohol. Subsequently, after 10 minutes incubation, samples were centrifuged 
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at 12,000 g for 15 minutes at 4°C, and supernatants were discarded. Finally, 
RNA pellets were washed with 0.2 ml 75% ethanol and dissolved in 25 μl 
RNase-free water.
Tissue RNA isolation
For total RNA isolation from tissue samples the InviTrap Spin Universal RNA 
Mini Kit from Invitek was used. 20 mg of fresh tissue was grounded under 
liquid nitrogen with a mortar and pestle. The powder was transferred into 
a 1.5 ml reaction tube and mixed with 900 μl lysis solution. To remove the 
genomic DNA the tube was centrifuged at maximum speed for 2 minutes. 
The supernatant was transferred in a new reaction tube, and 500 μl 100% 
ethanol was added. This mixture was loaded on a RTA Spin Filter, incubated 
for 1 minute and centrifuged for 1 minute at 10.000 g. After discarding the 
flow-through, two wash steps were performed. The first with 600 μl Wash 
Buffer R1 and the second with 700 μl Wash Buffer R2. The last washing step 
was repeated once. To eliminate any traces of ethanol, the tube was centri-
fuged at maximum speed for 5 minutes. Afterwards, total RNA was eluted 
by adding 40 μl RNase-free water onto the filter-membrane, incubating for 2 
minutes and centrifuging for 1 minute at 10,000 g. RNA was stored at -20°C.
2.2.11 Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to 
quantify the relative amount of specific mRNAs in certain samples. Therefore, 
isolated total RNA was reverse transcribed in cDNA, amplified with specific 
primers and normalized to HPRT, a ubiquitous expressed gene in all cell types 
(HPRT probe-number and primer sequence: see appendices 8.2).
For reverse transcription the RevertAid First Strand cDNA Synthesis Kit 
from Fermentas was used. Synthesis was done according to manufacturer’s 
protocol. In brief: 
cDNA Synthesis
as required    RNA (0.1 ng to 5 μg)
1 μl     oligo (dT) primer
to 12 μl    Water, nuclease-free
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4 μl    5x Reaction Buffer
1 μl    RiboLock RNase Inhibitor (20 u/μl)
2 μl    10mM dNTP Mix
1 μl    RevertAidTM M-MuLV Reverse Transcriptase 
     (200 u/μl)
After adding all components, the mixture was incubated for 60 minutes at 
42°C. The reaction was terminated by heating at 70°C for 5 minutes. After this 
incubation all mRNA fragments of the sample were transcribed into cDNA. 
This cDNA was used for further analyses by qRT-PCR.
qRT-PCR was done with Roche LightCycler 488 Probes Master. With this kit 
the following standard reaction was prepared: 
qRT-PCR         
1.5 μl    Water, PCR-grade
0.2 μl    primer forward (10 μM)
0.2 μl    primer reverse (10 μM)
5 μl    Probes Master
0.1 μl    Probe
3 μl    cDNA
For specific primers and probes see appendix 8.2. Relative gene expression of 
each gene was calculated as the ratio of gene of interest mRNA and hypo-
xanthine phosphoribosyltransferase (HPRT) mRNA, both determined in the 
same sample. qRT-PCR was performed with the LightCycler 480 Instrument. 
For all runs the standard Roche protocol Mono Color Hydrolysis Probes with 
45 amplification cycles was used. 
2.3 Immunological methods
2.3.1 CCL22 enzyme-linked immunosorbent assay (ELISA)
To measure the amount of CCL22 in different tissues, serum or the supernatant 
of cultured cells a CCL22 ”sandwich” ELISA (R&D System) was performed. Via 
“sandwich” ELISA a sample with an unknown amount of CCL22 is immobilized 
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on a polystyrene microtiter plate using a CCL22 specifi c capture antibody. 
After the antigen is immobilized, the detection antibody is added forming a 
complex with the antigen. The detection antibody is covalently linked to the 
enzyme horseradish peroxidase (HRP). By adding an enzymatic substrate, a 
visible signal can be detected which indicates by comparing to the signal of 
a CCL22 standard dilution the quantity of CCL22 in the sample. Therefore, a 
standard dilution was prepared for each ELISA. The standard dilution consists 
of clearly determined amounts of CCL22 (from 500 pg/ml to 0 pg/ml). The 
CCL22 standard dilution was done according to Figure 5.
500 pg/ml
300µl Std. 
Dilution
+
150 pg CCL22
150µl Std. 
Dilution
150µl Std. 
Dilution
150µl Std. 
Dilution
150µl Std. 
Dilution
150µl Std. 
Dilution
150µl Std. 
Dilution
150µl Std. 
Dilution
250 pg/ml 125 pg/ml 62,5 pg/ml 31,25 pg/ml 15,63 pg/ml 7,81 pg/ml 0 pg/ml
150µl 150µl 150µl 150µl 150µl 150µl
Figure 5: Standard dilution scheme. 500 pg/ml CCL22 was added to 300 µl standard dilution 
(donkey serum diluted 2:1 with PBS + 1% BSA). 150 µl of this fi rst solution was mixed with 150 µl 
standard dilution. Then 150 µl of this second solution was mixed with another 150 µl standard dilu-
tion and so forth. At the end eight different CCL22 standard dilutions (500 pg/ml, 250 pg/ml, 125 
pg/ml, 62.5 pg/ml, 31.25 pg/ml, 15.63 pg/ml, 7.81 pg/ml, and 0 pg/ml) were prepared. By comparing 
with this standard dilution, the unknown amount of CCL22 in a sample was verifi ed.
At the beginning of each ELISA, CCL22 capture antibody was diluted in PBS 
to a fi nal concentration of 2.0 μl/ml. 50 μl of this capture antibody solution 
per well was used to coat a 96 well microplate. The plate was sealed and 
incubated overnight at room temperature to enable binding of the antibody 
to the surface of the plate. On the next day the plate was washed three 
times with washing buffer (PBS + 0.05% Tween). To block any non specifi c 
binding sites on the surface of the plate, 150 μl blocking solution (PBS + 1% 
BSA) was added to each well. After 1 hour incubation the plate was washed 
again three times, and 50 μl sample (either pure or diluted with PBS + 1% 
BSA) or 50 μl standard dilution was added per well. 2 hours later the plate 
was washed again three times and incubated for 2 hours with 50 μl CCL22 
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detection antibody solution (diluted in PBS + 1% BSA to a final concentration 
of 50 ng/ml). By three times washing, all unbound detection antibody was 
removed. Afterwards, 50 μl enzyme solution (streptavidin HRP, diluted 1:200 
with PBS + 1% BSA) was added to each well and incubated in the absence 
of light for 20 minutes. To eliminate all unbound enzymes, the plate was 
washed again three times. Finally, 50 μl substrate solution (H2O2 diluted 1:1 
with tetramethylbenzidine) was added to each well. This substrate solution 
is converted by streptavidin HRP into a fluorescence signal. After 20 minutes 
the enzyme reaction was stopped by adding 25 μl per well stop solution (2 N 
H2SO4). Immediately after stopping the reaction, the optical density of each 
well was measured by using a microplate reader set to 450 nm + 570 nm as 
wavelength correction. The reference wavelength corrects for optical imper-
fections in the plate.
2.3.2 Cell proliferation BrdU ELISA
Tumor cell proliferation in vitro was measured by 5’-Bromo-2’-deoxyuridine 
(BrdU) cell proliferation ELISA kit from Roche. BrdU is a pyrimidine analogue 
that incorporates into the DNA of replicating cells instead of thymidine. By 
adding an anti-BrdU-peroxidase antibody and tetramethylbenzidin (TMB) as 
substrate the amount of incorporated BrdU can be measured with an ELISA 
reader. The obtained optical density (OD value) directly correlates with the 
cell proliferation rate. We used this technique to verify the proliferation rate 
of untreated and doxycycline-treated rtTA-CCL22-CT26 tumor cells. For this 
purpose, 40.000 tumor cells were cultured in a 96 well tissue-culture plate 
for 48 hours without or with different amounts of doxycycline in cell culture 
medium. 6 to 12 hours before analyzing the proliferation rate 7.5 μM BrdU 
was added to each well. After this labeling step the plate was centrifuged 
(400 g, 7 minutes) and the labeling medium was removed. Subsequently, 
the plate was dried at 60°C for one hour. Finally, the cells were fixated by 
adding FixDenat to each well, labeled with anti-BrdU antibody and incubated 
with TMB substrate solution according to the manufacturer’s protocol. The 
 reaction product was quantified in triplicates by measuring the absorbance at 
370 nm (+ 492 nm as wavelength correction) using an ELISA reader.
2.3.3 Cytokine assays of tissue lysates
Tissue homogenates were resuspended in lysis buffer (BioRad Laboratories) 
and centrifuged. Total protein concentration was measured by Bradford assay 
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(BioRad Laboratories). All samples were diluted to a protein concentration 
of 10 to 30 mg/ml, and CCL22 concentration was measured by ELISA (R&D 
Systems). The cytokine concentration was calculated as ng cytokine/g protein 
in the respective lysate.
2.3.4 Flow cytometry
Flow cytometry is a technique for analyzing and counting cells suspended in 
a fluid due to their physical and chemical differences. To analyze each single 
cell, a hydrodynamically-focused stream of liquid is generated. By use of this 
liquid stream, each cell passes single file through a laser light. At the point 
where the liquid stream passes through the laser light several detectors are 
installed. The so-called Forward Scatter (FSC) is in line with the light beam and 
measures cell volume. Perpendicular to the beam several additional detectors 
are located that presents the Side Scatter (SSC). The SSC provides informa-
tion about the granularity of a cell. Furthermore, different fluorescent detec-
tors connected with optical filters can detect emitted light from fluorescent 
chemicals found attached or in the cytosol of a cell. These fluorescent dyes 
are conjugated with antibodies that binds to certain cell surface markers such 
as CD3 or cytosolic molecules such as the transcription factor FOXP3. The flow 
cytometer FACS Canto II is equipped with three different laser lights (405 
nm, 488 nm and 633 nm) to illuminate cells tagged with a variety of different 
fluorescent dyes. All flow cytometry experiments were performed on this 
flow cytometer and analyzed with FlowJo software.
Analysis of cell surface antigens
Cells were diluted at 1 x 106 to 10 x 106 in 50 μl PBS. Flourochrome-conjugated 
monoclonal antibodies directed against the antigens of interest were added at 
a concentration of 10 μl/ml. After 30 minutes incubation at 4°C in the absence 
of light, cells were washed two times with PBS and finally re-suspended in 
PBS supplemented with 2% FCS for FACS analysis. 
Analysis of intracellular antigens
For analyzing the intracellular transcription factor FOXP3, intracellular 
staining was performed by using the FOXP3 Staining Buffer Set ( eBioscience). 
Initially, cell surface markers were labeled as described above. After surface 
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staining cells were centrifuged and re-suspended in fixation/permeabili-
zation reagent. The fixation reagent guarantees the fixation of all bound 
surface antibodies, whereas the permeabilization reagent permeabilizes the 
cell membrane to enable the staining of intracellular antigens. Cells were 
incubated for 30 minutes at 4°C in fixation/permeabilization reagent and 
washed twice with Perm-Buffer. After washing the cells were re-suspended in 
50 μl Perm-Buffer, and 10 μl/ml anti-FOXP3 antibody was added. Intracellular 
staining was performed for 30 minutes at 4°C in the absence of light. Finally, 
cells were washed two times with Perm-Buffer and re-suspended in PBS 
supplemented with 2% FCS for FACS analysis.
2.4 Cell culture
2.4.1 General culture conditions
All cell lines were cultured at 37°C and 5% CO2 in tissue culture flasks. Cell 
culture procedures were executed with sterile reagents under a laminar flow 
hood. The concentration and viability of cells was determined by trypan blue 
staining. Trypan blue is a reagent that is not absorbed by viable cell. In dead 
cells, by contrast, the dye could pass the membrane and thereby stains cells 
blue. Thus, dead cells are visible in a distinctive blue color under the micro-
scope and can be distinguished from viable cells. In order to stain death cells 
and count viable cells, 0,25% trypan blue in PBS was added in an appropriate 
dilution to cell suspensions. Cells were counted in a Neubauer hemocytometer 
under the microscope. The total number of cells per ml was calculated by multi-
plying the total cell number in one hemocytometer grid by the dilution factor 
and 104.
2.4.2 Murine tumor cell line
4T1 breast cancer (kindly provided by Dr. M. Wartenberg, Friedrich-Schiller-
University, Jena, Germany) Colon-26 (CT26) (Cell Lines Service, Heidelberg, 
Germany), Colon-26 with inducible CCL22 expression (rtTA-CCL22-CT26), B16 
melanoma F1 (LGC Promochem, Teddington, UK), mGC8 gastric cancer (kindly 
provided by Dr. med. J. Nöckel, LIFE-Center, University Clinic, Grosshadern, 
Germany) MethA sarcoma (kindly provided by Prof. W. Zimmermann, 
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LIFE-Center, University Clinic, Grosshadern, Germany) as well as Panc02 (kindly 
provided by Prof. C. Bruns, Department of Surgery, University of Munich, 
Germany) were maintained in complete DMEM or RPMI medium as described 
above. Tumor cells were split in a 1:10 dilution two times a week. Cells were 
detached with Trypsin-EDTA (0.25%), centrifuged (400 g, 7 minutes, 4°C), 
resuspended in fresh medium and transferred to culture flasks. All tumor cell 
lines were expanded for two to three passages upon receipt, stored in liquid 
nitrogen and freshly thawed prior each experiment.
2.4.3 Isolation of DC and T cells by magnetic cell separation
MACS (magnetic cell separation or magnetic-activated cell sorting) Technology 
from Miltenyi was used for the separation of magnetic labeled viable cells 
from lymphoid and non-lymphoid tissues.
For MACS separation cells are labeled with MACS MicroBeads which are 
superparamagnetic particles of approximately 50 nanometers in diameter 
and coated with antibodies against particular surface antigens. After cell 
labeling with these MicroBeads cells are applied on MACS columns. By a 
strong permanent magnet a high-gradient magnetic field is induced on 
the column matrix. Therefore, all labeled cells are retained in the column 
and all unlabeled cells pass through the column and can be collected. After 
removal of the column from the magnet, labeled cells can be released from 
the column and can also be collected. With MACS separation cells can be 
sorted by negative selection (= unbound fraction) and positive selection 
(= bound fraction).
Murine DC were separated from total spleen cells, lymphocytes or ex vivo 
tumor cell suspension with CD11c beads (= positive selection). Regulatory 
T cells were sorted from total spleen cells via a two-step procedure. First, 
non-CD4+ T cells were depleted by indirectly labeling with a cocktail of 
biotin-conjugated antibodies against CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR γ/δ and CD235a (glycophrin A) and Anti-Biotin MicroBeads 
(= negative selection). In a second step, the CD4+ flow-through fraction 
was labeled with CD25 MicroBeads for subsequent positive selection of 
CD4+CD25+ regulatory T cells. 
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In this study reagents from Miltenyi Biotec were used according to the 
manufacturer’s instructions, and all cell separations were done according to 
manufacturer’s protocol. In brief: Cells were labeled with the appropriate 
microbeads in MACS buffer for 15 minutes at 4°C and washed with MACS 
buffer. MS columns were placed in a magnet and equilibrated with 0.5 ml 
MACS buffer prior to loading the labeled cells in a volume of 0.5 ml. After 
washing the column with three times 0.5 ml MACS buffer, the column was 
removed from the magnet, and the bound fraction was eluted by flushing 
the cells in 1 ml MACS buffer through the column with the supplied plunger. 
If high purity of sorted cells was needed a second column purification step 
was performed. The purity of CD11c-sorted cells was 90% on average after 
one column purification. After a second column purification this purity was 
increased to more than 96%. 
In the case of the two-step Treg separation procedure cells were incubated 
with a biotin antibody cocktail (including CD8, CD14, CD16, CD19, CD36, CD56, 
CD123, TCR γ/δ and CD235a). After 10 minutes at 4°C anti-biotin microbeads 
and CD25-PE antibody were added and incubated for another 15 minutes 
at 4°C. Afterwards, cells were washed with MACS buffer. A LD column was 
placed in a magnet and equilibrated with 2 ml MACS buffer prior to loading 
the labeled cells in a volume of 0.5 ml. The column was washed with three 
times 1 ml MACS buffer, and the flow through was collected. In the second 
separation step these CD4+ cells were incubated with anti-PE microbeads for 
15 min at 4°C, washed with MACS buffer and applied in a volume of 0.5 ml 
onto a MS column (equilibrated with 0.5 ml MACS buffer). After washing the 
column, the column was removed from the magnet, and the bound fraction 
was eluted by flushing the cells in 1 ml MACS buffer through the column with 
the supplied plunger.
2.4.4 Toll-like receptor ligands treatment in vitro
For in vitro cultures murine tumor-infiltrating cells of CT26, B16 and Panc02 
tumors were treated with 5 μg/ml CpG 1826 (Coley Pharmaceutical Group), 
1000 U/ml murine interferon-alpha (IFN-α) (R&D Systems), 50 ng/ml murine 
interferon-gamma (IFN-γ) (Peprotech), 10 ng/ml murine IL-1β, IL-2, IL-6, IL-10 
or IL-12 (all Peprotech), respectively.
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2.4.5 Cell transfection
For cell transfection in vitro we cultured 1 to 4 x 104 cells per well in 96 
well plates. For one well following transfection mixture was prepared: 2.0 
to 5.0 μg plasmid was added to 10 μl Opti-MEM. The transfection reagent 
Lipofectamine 2000 was mixed with 10 μl Opti-MEM in a ratio of 5:1 to the 
amount of used plasmid DNA. Both mixtures were incubated for five minutes 
at room temperature, then combined and incubated for another 20 minutes. 
After 20 minutes the DNA and transfection reagent complex was added 
directly into the supernatant of cultured cells. Transfection efficiency was 
verified 24 hours post transfection. 
2.4.6 Conditioned medium
Conditioned medium (CM) was produced by stimulating 5 x 105 splenocytes 
of C57BL/6 mice with 5 μg/ml CpG 1826 (Coley Pharmaceutical Group) for 
2 hours, followed by extensive washing and culture in fresh medium for an 
additional 20 hours before removal and transfer of the supernatant into stim-
ulation assays of murine tumor-infiltrating cells.
2.5 Animal experimental procedures
2.5.1 Animals
For this study female BALB/c and C57BL/6 mice were purchased from Harlan-
Winkelmann (Borchen, Germany). IFN-I receptor (IFNAR)-deficient mice on 
C57BL/6 background were kindly provided by Dr. Z. Waibler (Paul-Ehrlich 
Institute, Langen, Germany). Mice were 6 to 10 weeks old at the onset of 
experiments. All mice were anesthetized with isoflurane for all interventions, 
but subcutaneous (s.c.) and intraperitoneal (i.p.) injections. Animal studies 
were approved by the local regulatory agency (Regierung von Oberbayern, 
Munich, Germany).
2.5.2 Organ and single cell preparation
Bone marrow-derived dendritic cell isolation: Femur and tibia were bilater-
ally dissected from sacrificed mice. Bones were cleaned with isopropanol, and 
bone marrow was extracted by flushing the bones with DC medium. The 
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obtained bone marrow was passed through a 40 μm cell strainer to gain 
a single cell suspension. Erythrocytes were lysed with ammonium chloride 
buffer, and remaining cells were cultured in DC medium supplemented with 
GM-CSF (20 ng/ml) and interleukin-4 (20 ng/ml). After seven days incubation 
differentiated DCs were harvested by gathering culture medium and rinsing 
culture flasks with cold PBS. 
Spleen cell isolation: Mice were sacrificed by cervical dislocation, and spleens 
were removed. To get a single cell suspension, the obtained spleens were 
passed through a 40 μm cell strainer. Next, erythrocytes were lysed by resus-
pending the cells in red blood cell lysis buffer. After 2 minutes incubation the 
lysis was stopped by washing cells with PBS. Splenocytes were kept in T cell 
medium for further experiments.
Lymph node cell isolation: Mice were sacrificed. Brachial, axillary and inguinal 
lymph nodes were collected and passed through a 40 μm cell strainer. The 
through flow (= single cell suspensions) was centrifuged and resuspended in 
T cell medium.
Tumor-infiltrating leukocytes isolation: Tumors were removed from sacrificed 
mice, mechanically disrupted and incubated with 1 mg/ml collagenase and 
0.05 mg/ml DNase (both Sigma Aldrich) at 37°C for 30 minutes. To obtain a 
single cell suspension, the tumors were passed through a 100 μm cell strainer 
followed by a 40 μm cell strainer. Suspended cells were layered on a gradient 
of 44% Percoll (upper phase) and 67% Percoll (lower phase) prior to centrifu-
gation at 800 g for 30 minutes. The leukocytes from the interphase were 
collected and used for flow cytometry analysis or cell culture. These obtained 
tumor-infiltrating immune cells typically contained 1-2% B220+ cells (B cells), 
17-20% CD11b+ cells (myeloid cells), 13-15% CD11c+ cells (DCs), 15% GR1+ 
cells (macrophages), 15% CD49b+ cells (NK cells), 5-6% CD3+CD4+ cells 
(Teffs) and 14% CD3+CD8+ cells (cytotoxic T cells). Defined by the expression 
of CD25 40% of the CD3+CD4+ fraction were Tregs (CD25+). The CD11c+ DC 
population can be subdivided in plasmacytoid DCs (pDCs) and conventional 
DCs (cDCs) according to the expression of B220. 20% of CD11c+ cells were 
pDCs (B220+) and 80% cDCs (B220-negative) (Figure 6). 
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Figure 6: FACS analysis of tumor-infi ltrating immune cells. To verify the composition of tumor-
infi ltrating immune cells three Panc02 tumors with a size of 100 mm2 were dissected, immune cells 
isolated from the tumor tissue by Percoll density centrifugation and analyzed by FACS. (A) Cells were 
stained for different surface markers that defi ne certain cell subsets of immune cells. The percentage 
indicates the amount of cells positive for a certain marker among all cells of the live gate. (B) The ratio 
of pDCs to cDCs was determined by the expression of B220. pDCs are the B220+ cells among all 
CD11c+ cells and cDCs are the B220-negative cells of all CD11c+ cells. (C) The ratio of Teffs to Tregs 
in tumor-infi ltrating immune cells was calculated by the expression of the surface marker CD25. Teffs 
are the CD25-negative cells among CD3+CD4+ cells and Tregs are all CD25+ cells of the CD3+CD4+ 
cells. For CT26 and B16 tumors comparable cell distributions were observed among tumor-infi ltrating 
immune cells. Error bars indicate SEM. 
2.5.3 Toll-like receptor stimulation of mice
The fully PTO-modifi ed CpG oligonucleotide 1826 (5’-TCCATGACGTT-
CCTGACGTT-3’) (Coley Pharmaceutical Group) was injected subcutaneously 
(100 μg CpG in PBS per mouse). Poly (I:C) (Amersham Bioscience) was applied 
intraperitoneally (250 μg in PBS per mouse).
2.5.4 Tumor experiments
For tumor induction 0.25 x 106 (CT26 and rtTA-CCL22-CT26) or 1.0 x 106 
(B16 and Panc02) tumor cells were injected subcutaneously into the 
flank. Mice with subcutaneous rtTA-CCL22-CT26 tumors were fed with 
a normal or 25 mg/kg doxycycline-containing diet (provided by ssniff 
 Spezialdiäten GmbH, Soest, Germany). The tumor size of individual 
tumors can be expressed as the product of the perpendicular diameters 
(= tumor area) or as the squared width divided by the bisected length 
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(= tumor volume) (Euhus et al., 1986). All tumor sizes in this work were 
expressed as tumor area.
2.6 Statistical analysis
All data are presented as mean +/- SEM and were analyzed as appropriate 
by unpaired Student’s t-test or by unpaired, one-way analysis of variance 
(ANOVA) with the Newman-Keuls multiple comparison test. Significance of 
survival time among different mouse groups was calculated by using the log-
rank test. In all analyses P < 0.05 was set as point for significance. All statistic 
calculations were done with Prism GraphPad. 
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3. Results
3.1 Source and impact of intratumoral CCL22
In this study we aimed to evaluate the impact of the chemokine CCL22 on 
anti-tumor immunity. To this aim we examined different mouse tumor models 
that allow evaluation of tumor progression in the presence or absence of 
CCL22.
3.1.1 CCL22 is expressed in murine tumors
As a fi rst step we verifi ed whether CCL22 is expressed in different subcu-
taneously established murine tumor entities in vivo. For this purpose six 
week old mice were subcutaneously injected with CT26 (colon carcinoma), 
B16 (melanoma), 4T1 (mammary cancer) or Panc02 (pancreatic cancer) tumor 
cells. After two weeks (approximate tumor size in length x width: 7 x 7 mm2) 
tumors were dissected, and CCL22 levels were determined in tumor lysates by 
ELISA (Figure 7). In all tested murine tumors substantial intratumoral levels of 
CCL22 were observed. Serum CCL22 concentrations were used as reference. 
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Figure 7: CCL22 levels in different murine tumor lysates. Intratumoral CCL22 levels of CT26 
(n=5), B16 (n=7), 4T1 (n=5) and Panc02 (n=7) tumor homogenates were measured via ELISA. 
Intratumoral CCL22 levels are shown in comparison with serum CCL22 levels of tumor-bearing mice 
(n=4). Bars (–) indicate the mean CCL22 concentration per overall tumor protein. 
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The highest expression of CCL22 was observed in Panc02 tumors, whereas 
the lowest expression of all analyzed tumors was seen in CT26 tumors (100 
times lower than in Panc02). In the spleen and the lymph nodes of tumor-
bearing mice CCL22 levels were similar to the CCL22 levels measured in 
healthy wild-type mice. In the spleen we typically detected 50 to 60 ng 
CCL22 per g total protein and in the lymph node 300 to 500 ng CCL22 per 
g total protein.
3.1.2  Tumor cell lines do not secrete CCL22 
Since CCL22 expression was observed in all tested murine tumor lysates, we 
aimed to identify the cellular source of intratumoral CCL22. In a fi rst step 
we verifi ed whether the tumor cells secrete CCL22. Therefore, we measured 
CCL22 levels in the culture supernatants of several different murine tumor 
cell lines. Strikingly, in all tested tumor cell supernatants no CCL22 expression 
was found (Figure 8). Thus, it is unlikely that the tumor cells themselves are 
the source of intratumoral CCL22.
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Figure 8: CCL22 levels in the culture supernatants of different tumor cell lines. Supernatants 
were analyzed for secretion of CCL22 by ELISA. CCL22 level in the supernatant of rtTA-CCL22-CT26 
tumor cells was used as positive control (for rtTA-CCL22-CT26 cell line description see methods 
part 2.2.8). Of each cell line 50.000 cells were cultured in triplicates in a 96 well plate. After two 
days CCL22 concentration in the culture supernatant was measured by ELISA. This experiment was 
repeated twice.
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3.1.3  Intratumoral dendritic cells express CCL22
Since tumor cells are probably not the source of intratumoral CCL22, we 
hypothesized that tumor-infi ltrating immune cells produce intratumoral 
CCL22. In murine tumors typically 2-4% of all cells are DCs, 2-3% are T cells, 
4% are NK cells, 1% are NKT cells and 3% are B cells (source: dissertation 
Michaela Golic, Division of Clinical Pharmacology, LMU, Munich, 2010). In 
addition, Tang and Cyster described DCs as the main producer of CCL22 in 
lymph nodes of healthy mice (Tang and Cyster, 1999). To investigate whether 
DCs are also responsible for CCL22 expression in murine tumor tissue, we 
sorted single cell suspensions of subcutaneous murine tumors for CD11c+ 
cells. CD11c is a commonly used murine DC surface marker. 
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Figure 9: CD11c mRNA levels of sorted single cell suspensions of subcutaneous murine 
tumors. We used qRT-PCR to verify the CD11c expression of sorted single cell suspensions of subcu-
taneous murine tumors (n=5). For this purpose we measured CD11c mRNA levels of unsorted, CD11c-
depleted and CD11c-enriched B16-infi ltrating leukocytes. HPRT was used for normalization. The 
shown data are the result of two independently performed experiments. Error bars indicate SEM. P 
value of sorted CD11c+ cells was calculated relative to CD11c-depleted cells (***p < 0.001).
The purity of sorted single cell suspensions of subcutaneous murine tumors 
was confi rmed by qRT-PCR and FACS analysis. We used qRT-PCR to measure 
CD11c mRNA levels of unsorted, CD11c-depleted and CD11c-enriched cells. As 
expected, low levels of CD11c were observed in unsorted tumor-infi ltrating 
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leukocytes, whereas almost no CD11c was detected in CD11c-depleted leuko-
cytes confi rming the absence of CD11c-positive cells in this fraction. CD11c-
enriched leukocytes showed high levels of CD11c mRNA (Figure 9).
The purity of the CD11c-enriched cells was further determined by FACS 
 analysis. Therefore, isolated tumor leukocytes were stained with a CD11c anti-
body before and after CD11c MACS sort. More than 97% CD11c-positive cells 
were detected in the CD11c-enriched fraction confi rming a high purity of this 
fraction. In unsorted tumor-infi ltrating leukocytes 11.2% of the analyzed cells 
were positive for CD11c (Figure 10).
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Figure 10: CD11c expression of unsorted and CD11c-sorted tumor-infi ltration leukocytes. 
Left panel: 11.2% of unsorted cells were CD11c-positive. Right panel: 97.8% CD11c-positive cells 
were detected after a two column MACS sort in the fraction of CD11c-enriched cells. Shown is one 
representative FACS blot.
We measured CCL22 mRNA levels in freshly isolated CD11c-sorted cells of B16 
tumors. In addition, CCL22 protein concentrations in the supernatants of ex 
vivo cultured sorted single cell suspensions of Panc02 tumors were deter-
mined by ELISA. Interestingly, CCL22 mRNA and protein were almost exclu-
sively expressed by tumor-infi ltrating CD11c+ cells (Figure 11), whereas almost 
no CCL22 was detectable in the CD11c-depleted fraction. In the unsorted 
condition only low CCL22 levels were observed. Thus, DCs appeared to be the 
exclusive producer of intratumoral CCL22.
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Figure 11: CCL22 mRNA and protein level of sorted single cell suspensions of subcuta-
neous B16 and Panc02 tumors. Mice received subcutaneously 1.0 x 106 B16 or Panc02 tumor 
cells (n=5, respectively). After tumors reached an average size of 100 mm2 in length x width, 
tumors were resected, and single cell suspensions were prepared. Cells were sorted for CD11c+ 
cells (purity > 96%) and immediately used either for mRNA isolation (B16) or cell culture (Panc02). 
CCL22 mRNA level of B16-sorted single cell suspensions were analyzed by qRT-PCR and normalized 
to HPRT mRNA. Supernatants of cultured single cell suspensions of Panc02 tumors were collected 
after 72 hours, and CCL22 concentration was measured by ELISA. Overall mRNA levels and protein 
levels of three conditions were analyzed in triplicates: unsorted, CD11c-depleted (CD11c -) and 
CD11c-enriched (CD11c +) cells. The shown results were confi rmed by repeating the experiment 
once. Error bars indicate SEM. P values of sorted CD11c+ cells were calculated relative to CD11c-
depleted cells (*p < 0.05; ***p < 0.001).
3.1.4 CCL22 increases tumor growth and decreases survival
Since CCL22 is known to be a potent attractor of Tregs, a cell type described 
to promote tumor growth, we aimed to analyze the impact of intratu-
moral CCL22 levels on tumor growth and overall survival of tumor-bearing 
mice. For this purpose we generated a novel tumor cell line, specifi ed as 
rtTA-CCL22-CT26 (see methods 2.2.8. and 2.2.9). These tumor cells were trans-
duced with a rtTA-CCL22 expression construct by lentiviral transduction. In 
cells that carry this construct, CCL22 expression is induced by doxycycline. In 
the presence of doxycycline the transactivator rtTA is active and promotes 
CCL22 expression, whereas in the absence of doxycycline rtTA is inactive, and 
induced CCL22 expression is blocked. The doxycycline-mediated inducibility 
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of CCL22 expression in rtTA-CCL22-CT26 tumor cells was verifi ed in vitro and 
in vivo. After the administration of 2 μg/ml doxycycline, CCL22 expression 
was highly up-regulated in the supernatant of in vitro-cultured rtTA-CCL22-
CT26 tumor cells. The same effect was observed in vivo. In rtTA-CCL22-CT26 
tumor-bearing mice fed with a diet containing 25 mg/kg doxycycline, high 
intratumoral CCL22 levels were observed in comparison to rtTA-CCL22-CT26 
tumor-bearing mice fed with normal diet (Figure 12).
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Figure 12: Doxycycline-dependent expression of CCL22 in vitro and in vivo. Left fi gure: 5 x 104
CT26 rtTA-CCL22-transduced tumor cells were cultured in a 96 well plate. 2 µg/ml doxycycline was 
added for 24 hours. CCL22 levels in the supernatant were measured in triplicates before and after 
doxycycline treatment. Right fi gure: Mice were subcutaneously injected with 1.0 x 105 rtTA-CCL22-
CT26 tumor cells and divided into two groups. One group was fed with a normal diet (n=7) and the 
other group with doxycycline-containing (25 mg/kg) diet (n=7). After tumors reached a size of 225 
mm2 (length x width), mice were euthanized, tumors dissected, and CCL22 level was measured in the 
tumor lysates by ELISA. These experiments were repeated several times. Shown are the results of one 
representative experiment. Error bars indicate SEM (**p < 0.01; ***p < 0.001).
We aimed to investigate whether CCL22 affects tumor growth and disease 
outcome. Therefore, we compared the tumor growth and survival rate of 
rtTA-CCL22-CT26 tumor-bearing mice with and without doxycycline-induced 
CCL22 up-regulation. Strikingly, the over-expression of CCL22 had a clear 
impact on tumor growth. Mice treated with a doxycycline diet showed a 
signifi cant faster tumor progression than mice fed with normal diet (Figure 13).
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Figure 13: Tumor growth of rtTA-CCL22-CT26 tumors. Mice were subcutaneously injected 
with 1.0 x 105 rtTA-CCL22-CT26 tumor cells. Subsequently, mice were divided into two groups. 
One group was fed with a normal diet and the other group with doxycycline-containing (25 mg/
kg) diet (n=7). Tumor size in length x width [mm2] was measured every second day. Tumor growth 
was monitored for 30 days. These data were confi rmed by repeating the experiment once. Error 
bars indicate SEM. P value of mice fed with normal diet was calculated according to mice fed with 
doxycycline diet (***p < 0.001).
In addition to tumor growth we determined the overall survival of rtTA-CCL22-
CT26 tumor-bearing mice. Consistently with tumor progression mice with 
doxycycline-induced intratumoral CCL22 over-expression showed a lower 
survival rate compared to mice fed with normal diet (Figure 14). 
Beside tumor growth we wanted to verify if CCL22 has also an impact on 
the ability of injected tumor cells to establish a solid tumor. Therefore, we 
used the same experimental model as described above, but injected only 
5 x 104 rtTA-CCL22-CT26 tumor cells instead of 1.0 x 105 cells. This low dose 
of tumor cells is typically not suffi cient to establish a tumor in the respective 
mouse. Indeed, fi ve mice out of seven rejected the tumor one week after 
a small tumor was palpable and stayed tumor-free in the group fed with 
normal diet. However, in the group fed with doxycycline diet and thereby 
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induced CCL22 over-expression only one mouse out of seven stayed tumor-
free and survived the monitored time period of 80 days (Figure 15). These 
results indicate that intratumoral CCL22 promotes tumor development. 
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Figure 14: Overall survival of rtTA-CCL22-CT26 tumor-bearing mice. 14 mice were subcutane-
ously injected with 1.0 x 105 rtTA-CCL22-CT26 tumor cells. Seven mice were fed with a normal diet, and 
seven mice were fed with doxycycline-containing diet. Tumor size and health conditions of mice were 
monitored for 60 days. After a tumor reached a maximum size of 225 mm2 in length x width, the corre-
sponding mouse was euthanized. One mouse in each group rejected the induced tumor and survived 
the monitored time period of 60 days. In two follow-up experiments the same trend was observed.
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Figure 15: Overall survival of mice treated with a low dose of rtTA-CCL22-CT26 tumor cells. 
14 mice were subcutaneously injected with 5 x 104 rtTA-CCL22-CT26 tumor cells. Seven mice were 
fed with a normal diet, and seven mice were fed with doxycycline-containing diet. Tumor size and 
health conditions of mice were monitored for 80 days. After a tumor reached a maximum size of 225 
mm2 in length x width, the corresponding mouse was euthanized. The shown results were confi rmed 
in three follow-up experiments.
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Next, we aimed to exclude that doxycycline itself contributes to the  observed 
tumor progression. Therefore, we used untransduced CT26 tumor cells. Mice 
were subcutaneously injected with 1.0 x 105 CT26 tumor cells, and tumor 
growth was monitored for 30 days. In accordance with the previous experi-
ment seven mice were fed with a doxycycline-containing diet, and seven mice 
received normal diet. We observed no differences in tumor growth between 
both groups indicating that doxycycline alone has no effect on tumor growth 
(Figure 16). Thus, the tumor-promoting effect is induced by CCL22 up-regula-
tion and not by feeding mice with a doxycycline-containing diet.
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Figure 16: Tumor growth of CT26 tumors treated with doxycycline. Mice were subcutaneously 
injected with 1.0 x 105 CT26 tumor cells. Subsequently, mice were divided into two groups. One 
group was fed with a normal diet (n=7) and the other group with doxycycline-containing (25 mg/kg) 
diet (n=7). Tumor size in length x width [mm2] was measured every second day. The experiment was 
repeated once. Error bars indicate SEM.
Finally, we verifi ed if CCL22 has a direct effect on the replication of tumor 
cells. Therefore, the in vitro proliferation rate of untreated and doxycycline-
treated rtTA-CCL22-CT26 tumor cells was measured by BrdU incorporation. 
No signifi cant differences in cell replication were seen (Figure 17, left panel). 
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Additionally, the amount of induced CCL22 was confi rmed by ELISA (Figure 17, 
right panel). In all conditions with doxycycline a high CCL22 expression was 
induced. Thus, CCL22 seems to have no direct effect on the proliferation rate 
of tumor cells. Only in the condition of tumor cells treated with the highest 
doxycycline dose a slight reduction of proliferation and CCL22 expression was 
observed indicating that high doxycycline levels could have a toxic effect. 
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Figure 17: Proliferation rate and CCL22 expression of rtTA-CCL22-CT26 tumor cells treated 
with doxycycline. 40.000 rtTA-CCL22-CT26 tumor cells were cultured in triplicates without or with 
increasing amounts of doxycycline as indicated. Left panel: After 48 hours the cell proliferation rate 
was measured by BrdU ELISA. The optical density (OD) indicates the amount of incorporated BrdU 
into the DNA and thereby directly correlates with the replication rate of the analyzed cells (for further 
information see material and methods 2.3.2). Right panel: The amount of produced CCL22 was 
quantifi ed by ELISA in the supernatant of the cultured tumor cells collected prior BrdU ELISA. Shown 
is one of two performed experiments.
In conclusion, we identifi ed DCs as the main producer of CCL22 in murine 
tumor tissue and showed here for the fi rst time that CCL22 promotes tumor 
growth and reduces overall survival of tumor-bearing mice.
3.2 TLR-mediated intratumoral CCL22 regulation
In the previously described experiments we investigated the impact of 
intratumoral CCL22 on tumor growth and overall survival. Additionally, we 
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identified DCs as the main producer of intratumoral CCL22. Experiments 
done by Raffael Thaler and Dr. David Anz showed that the treatment of CT26 
or B16 tumor-bearing mice with the synthetic TLR9 ligand CpG significantly 
reduces intratumoral CCL22 levels. CpG and other TLR agonists are known to 
suppress tumor growth and are currently investigated for their therapeutic 
 potential in humans and mice. 
TLR ligands such as CpG induce the secretion of inflammatory cytokines and 
thereby promote an anti-tumor immune response. For instance, the release of 
IFN-α after TLR activation enhances MHC-I expression on tumor cells. This in 
turn promotes cytotoxic T cell-mediated killing of these tumor cells. Overall, 
the precise mechanisms of TLR-induced tumor growth suppression are still 
not fully understood. Since CCL22 up-regulation promotes tumor growth and 
CCL22 down-regulation occurs during CpG-mediated tumor growth reduc-
tion, we hypothesized that CCL22 suppression is one of the major mechanisms 
that mediate TLR ligand-induced tumor regression. Therefore, the aim of the 
following experiments was to specify the mechanisms of TLR ligand-induced 
intratumoral CCL22 suppression and to verify the impact of this suppression 
on tumor immunity.
3.2.1 TLR ligands suppress intratumoral CCL22
First, we aimed to extend the previously in our group observed intratu-
moral CCL22 suppression to an additional experimental model. Since the 
measured CCL22 expression of Panc02 tumors is 10 times higher than in B16 
tumors and even 100 times higher than in CT26 tumors, we wanted to verify 
if TLR ligands could also suppress Panc02 intratumoral CCL22 expression. 
Therefore, we treated B16, Panc02 or CT26 tumor-bearing mice with CpG. 
Consistent with the data from Raffael Thaler and Dr. David Anz a strong 
CCL22 down-regulation after CpG treatment in B16 and CT26 tumors was 
observed (Figure 18). Strikingly, although Panc02 tumors had the highest 
CCL22 expression of all screened subcutaneously tumor models (see Figure 7), 
TLR stimulation induced a significant suppression of intratumoral CCL22 in 
Panc02 tumors. Thus, CpG-mediated suppression was observed in all three 
tested tumor entities. 
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Figure 18: CCL22 levels in different murine tumor lysates after CpG treatment. Mice bearing 
established tumors (7 x 7 mm2) received four injections of CpG (100 µg) at a four-day interval or 
stayed untreated. Two days after the last treatment B16 (n=6), Panc02 (n=5) and CT26 (n=10) intra-
tumoral CCL22 levels of CpG-treated mice were measured by ELISA in the tumor homogenates (black 
bars). These levels were compared with CCL22 levels of B16 (n=7), Panc02 (n=7) and CT26 (n=11) 
tumor homogenates of untreated mice (white bars). Error bars indicate SEM. P values were calculated 
relative to untreated mice (**p < 0.01; ***p < 0.001).
We also verifi ed whether intratumoral CCL22 expression is regulated by 
other TLR ligands than CpG. As shown in previous experiments by Raffael 
Thaler, the TLR3 and MDA-5 ligand poly (I:C) as well as the TLR7 ligand 
R848 suppress CCL22 in CT26 tumors. To evaluate whether other PRR 
ligands than CpG also suppress intratumoral CCL22 in murine tumors, we 
treated B16 tumor-bearing mice with the synthetic TLR3 and MDA-5 ligand 
poly (I:C). Therefore, mice with established B16 tumors received 250 μg 
poly (I:C). Two days after the injection of poly (I:C) tumors were dissected, 
and intratumoral CCL22 levels were  measured by ELISA. Like CpG, poly (I:C) 
treatment resulted in a suppression of intratumoral CCL22 in B16 tumors 
(Figure 19). This indicates that the TLR ligand-mediated CCL22 suppres-
sion is a general phenomenon and not specifi c for a certain TLR ligand or 
tumor entity.
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Figure 19: CCL22 levels in murine B16 tumor lysates after poly (I:C) treatment. Mice bearing 
established B16 tumors (7 x 7 mm2) received one injection of poly (I:C) (250 µg) or remained untreated. 
Two days after treatment intratumoral CCL22 levels were measured by ELISA in the tumor homo-
genates of treated (n= 5; black bars) and untreated mice (n= 5; white bars). Error bars indicate SEM. 
P value was calculated relative to untreated mice (*p < 0.05).
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Figure 20: CCL22 mRNA and protein level of sorted single cell suspensions of subcutaneous 
Panc02 tumors after CpG treatment. Mice received subcutaneously 1.0 x 106 Panc02 tumor cells 
(n=5). After tumors reached an average size of 100 mm2 in length x width, tumors were resected, 
and single cell suspensions were prepared. Subsequently, cells were sorted for CD11c (purity > 95%) 
and cultured in a 96 well plate. Triplicates of each fraction (unsorted, CD11c-depleted and CD11c-
enriched cells) were either treated with 5 µg/ml CpG (black bars) or stayed untreated (white bars). 
After 72 hours supernatants were collected, and the remaining cells were used for mRNA isolation. 
Finally, CCL22 levels in the obtained supernatants were measured by ELISA, and qRT-PCR with the 
isolated mRNA was performed to verify CCL22 mRNA expression in the cultured cells. As a reference 
gene we used HPRT. The shown data were confi rmed by repeating the experiment once. Error bars 
indicate SEM. P values of CpG-treated cells were calculated relative to untreated cells (*p < 0.05; **p 
< 0.01; ***p<0.001; ns indicates not signifi cant).
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Since we identified DCs as the main producer of intratumoral CCL22, we 
subsequently wanted to verify whether the treatment with TLR ligands can 
directly regulate the CCL22 secretion of tumor-infiltrating DCs. To answer this 
question, we used CD11c+ sorted single cell suspensions derived from subcu-
taneous Panc02 tumors. Unsorted, CD11c-depleted and CD11c-enriched intra-
tumoral leukocytes were cultured either with 5 μg/ml CpG or without CpG. 
After 72 hours the levels of secreted CCL22 in the cell culture supernatants 
were measured by ELISA. The remaining cells were used for mRNA isolation 
and subsequent qRT-PCR.
On mRNA levels we observed a significant downregulation of CCL22 mRNA after 
CpG treatment for all fractions (unsorted, CD11c-depleted and CD11c-enriched). 
However, the most striking CCL22 mRNA suppression was observed in the 
CD11c-enriched fraction. A significant CCL22 downregulation also occurred on 
protein level for cultured CD11c-enriched cells, whereas no significant changes 
were observed in the unsorted and CD11c-depleted fractions (Figure 20). These 
data show that TLR ligands can directly suppress the CCL22 secretion of DCs. 
3.2.2 CCL22 suppression is mediated by a soluble factor
Next, we wanted to know whether CCL22 suppression is mediated by a soluble 
factor that is released by DCs or if CpG has a direct intrinsic effect on DCs 
that suppresses CCL22 production. To answer this question, we stimulated 
splenocytes with or without CpG, removed CpG after two hours by extensive 
washing with PBS and harvested the supernatants after 24 hours. We termed 
these supernatants conditioned medium (CM) as they contain inflammatory 
factors induced by TLR stimulation, but not the TLR ligand itself. If CCL22 
suppression is mediated by a soluble factor produced by DCs after TLR stimula-
tion, this factor should be present in the conditioned medium of CpG-treated 
splenocytes. To verify this assumption, we cultured tumor-infiltrating immune 
cells with the conditioned medium of untreated and CpG-treated splenocytes 
(for cell composition of isolated tumor-infiltrating immune cells see Material 
and Methods part 2.5.2). Interestingly, the CCL22 secretion of tumor-infil-
trating immune cells cultured with conditioned medium of CpG-treated 
splenocytes was significantly reduced (Figure 21). This finding indicates 
that TLR ligand-mediated CCL22 suppression is induced by a soluble factor.
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Figure 21: CCL22 levels of tumor-infi ltrated leukocytes treated with conditioned medium. 
Tumor-infi ltrating immune cells of subcutaneous CT26, Panc02 and B16 tumors (n=5, respectively) 
were isolated ex vivo by density centrifugation and cultured in triplicates for three days with condi-
tioned medium gained from untreated splenocytes (CM) or conditioned medium obtained from 
CpG-treated splenocytes (CM CpG), respectively. Conditioned medium was obtained as described in 
the Material and Methods section. Subsequently, supernatant CCL22 levels were analyzed by ELISA. 
Shown are the representative results of two performed experiments. Error bars indicate SEM. P values 
of CM CpG-treated cells were calculated relative to CM-treated cells (**p < 0.01; ***p<0.001).
3.2.3 CCL22 suppression is mediated by IFN-α
Next, we performed stimulation experiments with several cytokines to iden-
tify the soluble factor that suppresses CCL22 secretion by tumor-infi ltrating 
DCs. Therefore, we isolated tumor-infi ltrating immune cells of freshly dissected 
subcutaneous Panc02 tumors by density centrifugation. After isolation these 
cells were cultured for three days with different recombinant cytokines that 
are typically released upon TLR stimulation. The appropriate cytokine concen-
trations were chosen according to titration experiments done by Stephan Eiber 
(Department of Clinical Pharmacology, LMU). In these experiments splenocytes 
of wild-type mice were treated with different amounts of the respective cyto-
kines and the extent of CCL22 suppression was verifi ed by ELISA. A signifi cant 
CCL22 suppression was observed at a dose of 1000 U/ml IFN-α, 50 ng/ml IFN-γ, or 
10 ng/ml IL-1β, IL-2, IL-6, IL-10 or IL-12, respectively (unpublished data). We used 
these concentrations to stimulate tumor-infi ltrating immune cells. IL-10, IL-12, 
IFN-γ	and IFN-α	stimulation induced a signifi cant CCL22 suppression. However, 
of all tested cytokines IFN-α was the most potent suppressor of CCL22 produc-
tion (Figure 22). Thus, we chose this cytokine for further investigations.
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Figure 22: CCL22 protein level of tumor leukocytes treated with different soluble factors. 
Panc02-infi ltrating immune cells of fi ve tumor-bearing mice were treated ex vivo with different soluble 
factors as indicated or remained untreated. ELISA was used to measure CCL22 levels in the superna-
tants of triplicates after a three-day incubation. Error bars indicate SEM. P value of treated cells was 
calculated relative to untreated cells (*p < 0.05; **p < 0.01).
After identifying IFN-α as a potent CCL22 suppressor for Panc02 immune cells, 
we examined if IFN-α has the same effect on tumor-infi ltrating immune cells 
of other tumor entities than Panc02. In analogy with the previous Panc02 
experiment we cultured tumor-infi ltrating immune cells from established 
subcutaneous CT26 and B16 tumors either in the presence or absence of 
IFN-α. As shown in Figure 23 we observed a signifi cant downregulation of 
CCL22 secretion after IFN-α treatment for both tumor entities. 
Additionally, we investigated if IFN-α could also directly suppress the CCL22 
secretion of intratumoral DCs. To answer this question, we sorted tumor-infi l-
trating immune cells of dissected Panc02 tumors for CD11c and cultured both 
CD11c-enriched and CD11c-depleted fraction with or without IFN-α. Strikingly, 
IFN-α treatment of CD11c+ cells caused a clear downregulation of CCL22 secre-
tion. In contrast, untreated as well as IFN-α-treated CD11c negative cells secreted 
almost no CCL22 (Figure 24). In conclusion, these experiments showed that IFN-α 
directly suppresses CCL22 secretion of ex vivo obtained intratumoral DCs. 
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Figure 23: CCL22 protein level of tumor leukocytes treated with IFN-α. Freshly isolated tumor-
infi ltrating immune cells of subcutaneous CT26 (n=5) and B16 tumors (n=5) were either treated with 
IFN-α (black bar) or remained untreated (white bar). After three days of incubation, supernatants 
of triplicates were collected and CCL22 protein levels in the supernatants were measured by ELISA. 
Shown are the representative data of two independently performed experiments. Error bars indicate 
SEM. P value of IFN-α-treated cells was calculated relative to untreated cells (***p < 0.001).
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Figure 24: CCL22 protein level of CD11c-sorted tumor leukocytes treated with IFN-α. CD11c-
sorted single cell suspensions (purity > 96%) of freshly isolated Panc02-infi ltrating immune cells of 
fi ve tumor-bearing mice were either treated with IFN-α (black bar) or remained untreated (white bar). 
After an incubation of three days, CCL22 protein levels in the supernatants were measured in trip-
licates by ELISA. Shown are the representative data of two independently performed experiments. 
The CD11c-negative fraction includes B cells, T cells, NK cells and macrophages (see also material and 
method part 2.5.2). Error bars indicate SEM. P value of IFN-α-treated cells was calculated relative to 
untreated cells (**p < 0.01).
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3.2.4 TLR-induced CCL22 suppression is abrogated in IFNAR mice
To test the impact of IFN-α on TLR-mediated intratumoral CCL22 downregu-
lation, we performed in vivo tumor experiments with interferon-receptor-
type-1 defi cient (IFNAR) mice, kindly provided by Dr. Z. Waibler (Paul-Ehrlich 
Institute, Langen, Germany). IFNAR mice carry a knockout mutation in the 
coding region of the type-1-interferon-receptor. The knockout was achieved 
by integrating a neomycin cassette into exon 3 of the type-1-interferon-
receptor gene. Since these mice cannot respond to IFN-α and IFN-β (Müller 
et al., 1994), no suppression of intratumoral CCL22 should be induced by TLR 
stimulation.
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Figure 25: Intratumoral CCL22 levels of poly (I:C)-treated B16 tumor-bearing wild-type and 
IFNAR mice. Subcutaneous B16 tumors (1.0 x 106 cells per mouse) were induced in C57BL/6 (n=10) 
or type-I-interferon-receptor knockout (IFNAR) mice (n=10). On day nine after tumor induction both 
groups were either treated with poly (I:C) (250 µg per mouse) or remained untreated. Seven days 
after poly (I:C) injection, tumors were prepared, and CCL22 levels of homogenates were measured 
by ELISA. Also the tumor growth was monitored during the entire experiment (see next fi gure). Due 
to limited mouse availability this experiment was performed once. Error bars indicate SEM. P values of 
poly (I:C)-treated mice were calculated relative to untreated mice (*p < 0.05).
To verify this hypothesis, we subcutaneously injected B16 tumors into 
 IFNAR and wild-type C57BL/6 mice. Both mice strains share the same 
 genetic background. After a solid tumor was established, mice of both 
strains were either treated with the TLR3 and MDA-5 ligand poly (I:C) 
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or stayed untreated. We monitored tumor growth every second day and 
measured intratumoral CCL22 levels after dissecting the tumors 16 days 
after tumor induction. 
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Figure 26: Tumor growth of poly (I:C)-treated B16 tumor-bearing wild-type and IFNAR 
mice. Subcutaneous B16 tumors were induced in C57BL/6 wild-type (n=10) as well as IFNAR mice 
(n=10), and poly (I:C) treatment was done as described above. Tumor growth in length x width 
[mm2] was measured continuously for 16 days after tumor injection. Error bars indicate SEM. P values 
were calculated relative to untreated mice (***p < 0.001, ns indicates not signifi cant).
Consistent with previous reports, poly (I:C) leads to a signifi cant tumor 
growth reduction in wild-type mice compared to untreated tumor-bearing 
wild-type mice. The tumor growth of IFNAR mice was accelerated compared 
to wild-type mice (Figure 26). However, this observation is a known effect 
in IFNAR mice. Since IFN-α is involved in many anti-tumoral immune regu-
lations such as anti-angiogenesis, cell differentiation, tumor cell apop-
tosis as well as DC maturation, survival and antigen cross-presentation 
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IFN-α-unresponsiveness leads to increased tumor growth in IFNAR mice 
(Tarhini et al., 2012; Kirkwood et al., 2002; Wang et al., 2007; Paquette et 
al., 1998; Krown et al., 1984). 
Strikingly, the TLR ligand-mediated suppression of intratumoral CCL22 
was not only abrogated in IFNAR mice, but even increased (Figure 25). 
Furthermore, no anti-tumoral therapeutic effect of TLR treatment was seen 
in  tumor-bearing IFNAR mice (Figure 26). In summary, these results indi-
cate that IFN-α is a key mediator in TLR ligand-induced intratumoral CCL22 
suppression. Additionally, CCL22 suppression could contribute to the thera-
peutic effects of TLR ligands. 
3.2.5 CCL22 contributes to TLR-mediated anti-tumor immunity
The previously described tumor experiment in IFNAR mice showed that IFN-α 
mediates the PRR-induced CCL22 suppression in tumor-bearing mice. In addi-
tion, the therapeutic effect of poly (I:C) treatment was abrogated in IFNAR 
mice. However, the contribution of CCL22 suppression blockade to this effect 
is very unclear since a type-1-interferon-receptor knockout influences many 
pathways in tumor-bearing mice. To evaluate the contribution of CCL22 
suppression to the PRR-induced anti-tumor immune reaction, we performed 
an additional TLR stimulation tumor experiment with the novel generated 
rtTA-CCL22-CT26 tumor cell line (see Materials and Methods part 2.2.9). 
As shown in Figure 12, by feeding rtTA-CCL22-CT26 tumor-bearing mice with 
doxycycline, intratumoral CCL22 was up-regulated. We assumed that this 
up-regulation would abrogate TLR-mediated suppression of CCL22. Since in 
this experiment only the CCL22 suppression is blocked, the exclusive impact 
of CCL22 in CpG-induced tumor therapy could be elucidated. 
We injected mice with 2.5 x 105 rtTA-CCL22-CT26 tumor cells subcutaneously. 
Overall 56 mice received tumors. 28 mice were fed with normal diet, and 28 
mice were fed with doxycycline-containing diet. Three weeks after tumor 
induction 14 mice of each group were treated three times every third day 
with CpG. Tumor growth in length x width [mm2] was monitored continu-
ously for 32 days after tumor injection.
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As expected in the group with no induced CCL22 over-expression (= fed 
with normal diet), CpG treatment resulted in a clear tumor growth reduc-
tion compared to untreated mice. Strikingly, in the group with doxycycline-
induced CCL22 over-expression the CpG treatment had only a very poor 
therapeutic effect (Figure 27). 
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Figure 27: Tumor growth of CpG-treated rtTA-CCL22-CT26 tumor-bearing mice. BALB/c 
mice were inoculated with subcutaneous rtTA-CCL22-CT26 tumors and fed with a normal (n=28) or 
doxycycline-containing (n=28) diet. On day 21 after tumor induction both groups were either treated 
three times at a three-day interval with CpG (100 µg per mouse) or remained untreated. For each 
group the mean tumor growth of untreated and CpG-treated mice is shown. Tumor size [mm2] was 
measured every second day. Shown are the combined data of three independently performed experi-
ments. Error bars indicate SEM. P value of CpG-treated mice fed with normal diet was calculated 
relative to untreated mice fed with normal diet and CpG-treated mice fed with doxycycline diet (*p 
< 0.05, ns indicates not signifi cant).
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After the tumor growth of all mice was monitored for 32 days, we wanted 
to verify if the doxycycline-induced over-expression of CCL22 indeed blocked 
the CpG-mediated CCL22 suppression in the tumors. Therefore, the mice 
were sacrificed, tumors dissected and CCL22 levels were measured in the 
obtained tumor lysates. As expected in mice fed with a normal diet, CpG 
treatment significantly reduced intratumoral CCL22 expression (Figure 28 
A, white and black bar on the left). However, in mice fed with doxycycline 
no significant difference in intratumoral CCL22 expression was observed 
between CpG-treated and untreated mice (Figure 28 A, white and black bar 
on the right). Thus, the doxycycline-induced CCL22 over-expression efficiently 
compensated the CpG-mediated CCL22 suppression in the tumor tissue. In 
summary, these results show that by blocking the TLR ligand-induced intra-
tumoral CCL22 suppression, the TLR ligand-caused anti-tumor immunity is 
significantly reduced. Thus, the suppression of intratumoral CCL22 is impor-
tant for TLR  ligand-mediated anti-tumor immunity. 
3.2.6 Suppression of intratumoral CCL22 reduces intratumoral Treg numbers
As mentioned above the chemokine CCL22 attracts Tregs. Consistent with 
the suppression of CCL22 after TLR stimulation previous experiments done 
by Dr. David Anz have shown that TLR stimulation also selectively reduces 
the amount of intratumoral Tregs. Since doxycycline-induced CCL22 
over-expression compensates TLR ligand-induced CCL22 suppression, we 
hypothesized that thereby also the reduction in Treg tumor infiltration 
is abolished. To verify this assumption, we used flow cytometry to deter-
mine the amount of intratumoral Tregs. These levels were compared with 
the corresponding intratumoral CCL22 levels measured by ELISA. For this 
experiment we used the same mouse groups as described in the last result 
subsection (see part 3.2.5). 
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Figure 28: Intratumoral CCL22 and Treg levels of mice bearing rtTA-CCL22-transduced 
CT26 tumors. Mice with subcutaneous rtTA-CCL22-CT26 tumors were fed with a normal (n=28) or 
doxycycline-containing (25 mg/kg) diet (n=28). On day 21 after tumor induction both groups were 
either treated three times at a three-day interval with CpG or remained untreated. One day after the 
last injection, tumors were prepared. (A) CCL22 levels of homogenates were measured by ELISA, and 
(B) intratumoral levels of Tregs were analyzed by fl ow cytometry. Tregs were defi ned as FoxP3+ cells 
of CD3+CD4+ cells of the live gate. Shown are the combined data of three independently performed 
experiments. Error bars indicate SEM. P values were calculated relative to untreated mice (*p < 0.05; 
**p < 0.01).
As expected the CpG-mediated intratumoral CCL22 suppression (Figure 28 A, 
white and black bar on the left) led to a signifi cant decrease of intratumoral 
Treg counts in tumor-bearing mice (Figure 28 B, white and black bar on the 
left). In contrast, the levels of other T cell subsets such as CD8+ cytotoxic T cells 
were not altered (data not shown). However, consistent with the unchanged 
intratumoral CCL22 levels of CpG-treated doxycycline fed mice, also the 
amount of intratumoral Tregs remained unchanged (Figure 28 B, white and 
black bar on the right). Thus, in mice fed with doxycycline CpG treatment 
failed to reduce intratumoral Treg numbers. Figure 29 shows a representa-
tive FACS blot of each group. In conclusion, blockade of TLR ligand-mediated 
CCL22 suppression abolished the reduction of intratumoral Tregs and by this 
mean eventually abrogated the therapeutic effect of TLR stimulation. 
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Figure 29: Intratumoral Treg levels of CpG and untreated mice bearing rtTA-CCL22-CT26 
tumors. Mice with subcutaneous rtTA-CCL22-CT26 tumors were fed with a normal (n=28) or doxy-
cycline-containing (25 mg/kg) diet (n=28). On day 21 after tumor induction both groups were either 
treated three times at a three-day interval with CpG or remained untreated. One day after the last 
injection, tumors were prepared and analyzed by FACS. The indicated numbers represent the percent 
of Tregs, defi ned as FOXP3+ cells, among CD3+CD4+ cells of the live gate. Shown is one representa-
tive FACS blot of each group.
3.3 Mouse models to verify the function of CCL22 in tumors
The experiments shown previously illustrated the impact of intratumoral 
CCL22 over-expression. For these experiments we used a tumor cell line with 
inducible CCL22 expression. However, as shown in part 3.1.2, not the tumor 
cells are the main producer of CCL22 in vivo, but tumor-infi ltrating DCs. To 
further investigate the impact of intratumoral CCL22, we decided to use 
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two different approaches. First, we generated a novel mouse line with DC 
specific CCL22 over-expression to verify the impact of increased DC-produced 
CCL22. Secondly, we used a newly generated CCL22 KO mouse line (National 
Institutes of Health) to investigate the effect of CCL22 depletion on tumor 
development and tumor growth.
3.3.1 Generation of a transgenic mouse with inducible DC-specific CCL22 
 expression 
To generate a novel mouse line with inducible DC-specific CCL22 over-expres-
sion, two different mouse lines were needed, one mouse line transgenic for 
the construct CD11c-rtTA and one transgenic for TRE-CCL22. The CD11c-rtTA 
mouse was kindly provided by Dr. Leo Lefrancois (Connecticut, USA), and 
the TRE-CCL22 mouse was newly generated in cooperation with Dr. Marlon 
Schneider (Genzentrum, LMU). 
In the CD11c-rtTA mouse CD11c regulates the expression of the tet-On 
advanced transactivator (rtTA). CD11c is a promoter sequence specifically 
active in dendritic cells. Thus, rtTA should be only expressed in DCs. In the 
TRE-CCL22 mouse the tetracycline response element (TRE) regulates the 
expression of CCL22. The activator element rtTA can bind the antibiotic doxy-
cycline. The antibiotic binding leads to a conformation change of rtTA. This 
 conformation change enables rtTA to bind to the promoter TRE which in turn 
is activated and initiates CCL22 expression. Hence, in a dendritic cell containing 
both constructs, CD11c-rtTA and TRE-CCL22, there are two possible scenarios. 
In the absence of doxycycline, TRE-mediated expression of CCL22 is blocked 
(Figure 30), whereas in the presence of doxycycline TRE activates expression of 
CCL22 (Figure 31). In all other cells CD11c is not active, and the activator rtTA 
is not expressed. Thus, in these cells CCL22 expression is not induced in the 
presence of doxycycline. 
73
Results
CD11c rtTA
rtTA
rtTA
rtTA
rtTA
rtTA
rtTA
rtTA
TRE CCL22
Figure 30: The CC11c-rtTA-TRE-CCL22 system in the absence of doxycycline. Shown is a DC 
bearing both constructs, CD11c-rtTA and TRE-CCL22. The expression of the activator element rtTA is 
mediated by the DC specifi c CD11c promoter. rtTA in turn activates the expression of the TRE regu-
lated gene of interest (CCL22). However, in the absence of doxycycline the activator rtTA is unable to 
bind to TRE, and CCL22 expression is blocked.
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Figure 31: The CC11c-rtTA-TRE-CCL22 system in the presence of doxycycline. Doxycycline 
binds to rtTA and thereby facilitates a conformation change of the activator. This change enables rtTA 
to bind to TRE and activates DC-specifi c CCL22 over-expression. 
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TRE-Tight CCL22 Vector
The first step in establishing a doxycycline inducible CCL22 expression system 
was to integrate the cDNA sequence of murine CCL22 into a pTRE-Tight Vector 
provided by Clontech (Cat. # 631059). CCL22 was cloned downstream of the 
TRE promoter to enable TRE regulated expression of CCL22. We used the PCR 
primers CCL22-For-NotI and CCL22-Rev-SalI (for sequence see appendices 8.1) 
for cloning the murine CCL22 cDNA into the pTRE-Tight vector. After positive 
clone selection via ampicillin and plasmid amplification, obtained plasmids 
were verified by sequencing. In all tested plasmids correct CCL22 cDNA integra-
tion was observed. Additionally, no mutations in CCL22 or the flanking region 
of CCL22 were detected (for sequencing data see appendices section 8.3).
 
pTRE-Tight CCL22 transgenic mouse
The next step was the generation of a transgenic mouse. Mouse genera-
tion was done by Dr. Marlon Schneider (Genzentrum - LMU). The TRE-CCL22 
segment was cut out of the pTRE-Tight-CCL22 vector by ApaLI digest. This 
segment was used for microinjection. In this procedure an elusion of the 
segment was injected into the pronuclei of fertilized eggs. Injection was done 
at the stage of development when mammalian ova have two pronuclei, one 
from each gamete, which will later fuse to form the diploid nucleus. The 
fertilized eggs were obtained from donor mice. After microinjection the eggs 
were transferred to the oviducts of pseudopregnant foster mothers. The 
offspring resulted from these injected eggs were screened for the transgenic 
TRE-CCL22 construct by PCR using the primer pair TRE-F/TRE-R (sequence: see 
appendices 8.1). Overall, we identified one male mouse to carry the transgene. 
This founder animal was crossed with female CD11c-rtTA mice. The offspring 
were screened for both transgenes by PCR with the primer pairs TRE-F/TRE-R 
and rtTA-F/rtTA-R (sequence: see appendices 8.1). Double positive mice are 
heterozygous for both, pTRE-CCL22 and CD11c-rtTA (CD11c-rtTA-CCL22 mice).
Characterization of the CD11c-rtTA-CCL22 mouse
After the identification of double transgenic mice, these mice were used for 
further characterization. To verify if the transgene was integrated correctly 
into the mouse genome, the transgenic sequence was analyzed by sequencing 
using the primer pTRE-Seq-For and pTRE-Seq-Rev. In all analyzed mice correct 
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TRE-CCL22 cDNA integration was observed. Only in the multiple cloning site 
downstream of the CCL22 sequence a base transition (C κ	T) was detected. 
However, this point mutation does not affect the functionality of the 
TRE-CCL22 segment (for sequencing data see appendices section 8.4). Next, 
we analyzed the expression of the rtTA transactivator in CD11c-rtTA-CCL22 
mice RNA was isolated from splenocytes of wild-type and rtTA transgenic 
mice, transcribed in cDNA and used for qRT-PCR (probe-number and primer 
sequence: see appendices 8.2). The PCR confi rmed a high rtTA expression in 
all analyzed CD11c-rtTA-CCL22 mice compared to wild-type mice (Figure 32).
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Figure 32: rtTA Expression level of splenocytes. Shown is the expression of rtTA in the spleen of 
two wild-type and two rtTA transgenic mice. The expression was measured by qRT-PCR using Roche 
probe number 80 and normalized with the ubiquitous expressed mRNA of HPRT. The representative 
data of two performed experiments are shown. Error bars indicate SEM. P value was calculated rela-
tive to wild-type mice (***p < 0.001)
Subsequently, the inducibility of CCL22 was checked. Therefor, an in vitro and 
an in vivo assay was performed. For the in vitro experiments spleens from 
wild-type, TRE-CCL22 and CD11c-rtTA-CCL22 mice were isolated. Whole sple-
nocytes and sorted DCs were cultured both in the absence and in the presence 
of doxycycline. 48 hours later CCL22 levels were measured in the supernatant 
by ELISA. As expected no CCL22 induction was observed for splenocytes and 
CD11c-sorted DCs in wild-type and CCL22 transgenic mice. However, also in 
the CD11c-rtTA-CCL22 double transgenic mice no induction was detected in 
the supernatant of splenocytes and DCs alone (Figure 33 and Figure 34).
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Figure 33: CCL22 expression in the supernatant of cultured splenocytes after 48 hours. The 
inducible CCL22 expression by doxycycline of wild-type, TRE-CCL22 transgenic and CD11c-rtTA-CCL22 
double transgenic splenocytes was compared. For each group splenocytes were isolated from fi ve 
mice and cultured in triplicates for 48 hours. In each case the expression level of the untreated condi-
tion was set to 100%, and the appropriate doxycycline-treated condition was set in relation to it. The 
experiment was repeated twice.
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Figure 34: CCL22 expression in the supernatant of cultured DCs after 48 hours. The induc-
ible CCL22 expression by doxycycline of wild-type, CCL22 transgenic and CD11c-rtTA-CCL22 double 
transgenic DCs was compared. DCs were isolated by sorting splenocytes for CD11c (purity >90). For 
every group DCs were isolated from three mice and cultured in triplicates for 48 hours. In each case 
the expression level of the untreated condition was set to 100%, and the appropriate doxycycline-
treated condition was set in relation to it. The described experiment was repeated twice.
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Figure 35: CCL22 expression level in lymph nodes, spleen, lung and serum of wild-type and 
CD11c-rtTA-CCL22 transgenic mice. To measure doxycycline-mediated CCL22 induction, both 
wild-type (n=8) and CD11c-rtTA-CCL22 transgenic mice (n=8) were separated into two groups. One 
group received doxycycline enriched diet (25 mg/kg) and the other group normal diet. Mice were 
sacrifi ced after one week, and chemokine levels were measured by ELISA. In each case the expression 
level of the untreated condition was set to 100%, and the appropriate doxycycline-treated condition 
was set in relation to it. The illustrated results were confi rmed in two follow-up experiments.
For measuring CCL22 induction, in vivo wild-type and CD11c-rtTA-CCL22 trans-
genic mice were fed with a doxycycline-containing diet as well as a normal 
diet. After one week all mice were sacrifi ced, and the CCL22 levels in serum, 
lung, spleen and lymph nodes were measured by ELISA. In case of a functional 
CD11c-rtTA-CCL22 system double transgenic mice should show an induction 
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of CCL22 expression after doxycycline treatment. No induction in lung, spleen 
and lymph nodes was detectable (Figure 35).
Taking together the in vitro and in vivo data, both approved no functional 
CCL22 induction in double transgenic mice, the integrated TRE-CCL22 element 
seems not to be activated by doxycycline. Due to correct rtTA expression 
(Figure 32) and precise integration of the TRE-CCL22 sequence (see appen-
dices section 8.4) the most likely reason for missing induction seems to be the 
integration site of the TRE-CCL22 element. As a result of random genomic 
 integration of the transgene in the process of generating a transgenic mouse, 
the transgene can integrate into a silenced region of the mouse genome. 
To solve this problem, two more TRE-CCL22 transgenic mouse founder were 
generated. However, similar to the first founder, no CCL22 induction was 
observed. Therefore, we decided to simplify the transgenic approach. To 
circumvent the problems mentioned above, we intended to generate a new 
mouse line with DC specific CCL22 expression without inducibility.
3.3.2 Generation of a transgenic mouse with a stable non-inducible DC- 
 specific CCL22 expression 
Since the CD11c-rtTA-CCL22 mouse showed no inducible CCL22 over-expres-
sion, a new transgenic mouse approach was established. To simplify the tissue 
specific CCL22 expression system, we excluded the rtTA-dependent induc-
ible expression system. Instead CCL22 should be expressed directly under 
the control of the DC-specific promoter CD11c. In such an expression system 
CCL22 is produced permanently and specifically by all CD11c+ DCs. 
To achieve the DC specific CCL22 expression, we used a 5.5-kb fragment that 
contained the 5’ region of the mouse CD11c gene (kindly provided by Dr. 
Thomas Brocker, Munich, Germany). The CD11c segment was cloned into a 
pBSbluescript vector that contained a rabbit beta-globin gene fragment. This 
fragment contained a multiple cloning site and provided the transgene with 
an intron and a polyadenylation signal. CCL22 was cloned into the multiple 
cloning site by using the restriction enzyme EcoRI. Therefore, CCL22 cDNA was 
amplified with the two PCR primers CCL22-EcoRI-for and CCL22-EcoRI-rev (for 
primer sequence see appendix 8.1), cut with EcoRI and ligated with the EcoRI 
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digested pBSbluescript vector. After positive clone selection via ampicillin and 
plasmid amplifi cation, obtained plasmids were verifi ed by sequencing. In the 
plasmids of all tested clones CCL22 sequence was integrated correctly.
In a next step the functionality of the newly generated CD11c-CCL22 construct 
was verifi ed in vitro. Therefore, we used the immortalized DC cell line DC2.4. 
Similar to primary DCs DC2.4 express high levels of CD11c (Figure 36). However, 
in contrast to primary DCs, this immortalized cell line lacks CCL22 production. 
Thus, this cell line is well suited to test the functionality of the CD11c-CCL22 
fragment. We used Lipofectamine 2000 Transfection Reagent to transfect 
DC2.4. 24 hours post transfection CCL22 levels were measured in the super-
natant of the cultured cells (Figure 37). Compared to untransfected cells we 
observed high CCL22 levels in the supernatant of CD11c-CCL22 transfected 
cells indicating that the new transgenic construct is functional in DCs. 
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Figure 36: CD11c expression of DC2.4 cells. Left panel: CD11c-stained DC2.4 cells. Right panel: 
DC2.4 cells mixed with non-CD11c-expressing cells (here: Panc02 tumor cells) to exclude unspecifi c 
binding of the CD11c antibody. DC2.4 cells were mixed with Panc02 cells in a ratio of 10 to 1. 87% of 
the analyzed cells were positive for CD11c, refl ecting the initial ratio of Panc02 and DC2.4 cells. Cells 
were analyzed in triplicates. Shown is one representative FACS blot of each condition.
Since the functionality of the CD11c-CCL22 construct was proved in vitro, we 
started to generate the CD11c-CCL22 transgenic mouse. Mouse generation 
by microinjection (as described above) was done by Dr. Marlon Schneider 
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(Genzentrum - LMU). The injected transgenic cassette was cut out of the 
pBSbluescript vector with the restriction enzymes NotI and XhoI resulting 
in a 6,5-kb long fragment. The generation of the CD11c-CCL22 transgenic 
mouse line is still in progress, and fi rst offspring is expected at the beginning 
of next year (2013). After establishing the new mouse line and verifying DC 
specifi c CCL22 over-expression in vivo, these mice should be used for tumor 
experiments. Thereby, the impact of CCL22 on tumor development and tumor 
growth should be illustrated in a DC-specifi c setting.
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Figure 37: CCL22 expression of DC2.4 transfected cells. The CD11c-CCL22 construct was 
transiently integrated into DC2.4 cells. The plasmid integration was done by transfection with 
Lipofectamine 2000 Transfection Reagent. 24 hours before (= untransfected) and 24 hours after 
transfection the CCL22 levels in the cell culture supernatant of triplicates were measured via ELISA. 
Error bars indicate SEM. P value was calculated relative to untransfected cells (**p < 0.01).
3.3.3 CCL22 gene knockout mouse
Beside the tissue specifi c over-expression of CCL22 the role of this chemokine 
for tumor immunity should be verifi ed by using a CCL22 gene knockout mouse 
(CCL22 KO). Therefore, we ordered a up to now undescribed CCL22 KO mouse 
from the NIH (National Institutes of Health) founded non-profi t Knockout 
Mouse Project (www.komp.org). The CCL22 gene knockout was realized by 
replacing the CCL22 genomic coding region by homologous recombination. 
CCL22 was exchanged by a reporter (lacZ) plus selection (neomycin) frag-
ment. Mice genotyping was done by PCR with two primer pairs, one primer 
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pair specifi c for the selection fragment ( NeoinF and NeoinR) and one pair 
specifi c for the coding region of CCL22 (TDF and TDR; for primer sequences 
see appendix 8.1). With these two primer pairs we were able to distinguish 
between wild-type, heterozygous and CCL22 KO homozygous mice.
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Figure 38: CCL22 levels in spleens, lungs, lymph nodes, peyer’s patches and Sera of CCL22 
KO mice. 6 week old wild-type (n=2), CCL22 KO heterozygous (n=2) and CCL22 KO homozygous 
mice (n=2) were sacrifi ced and spleen, lung, lymph nodes (LN), Peyer’s patches (PP) and serum 
were obtained. The obtained organs were lysed, and CCL22 levels in the lysates and the sera were 
measured by ELISA. Shown are the representative results of two independent experiments. Error 
bars indicate SEM. P values were calculated relative to wild-type mice (**p < 0.01, ***p<0.001, nd 
indicates not detectable).
Since the CCL22 KO mouse line was newly generated, the fi rst upcoming 
experiment was to verify the functionality of the CCL22 knockout. Therefore, 
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we dissected spleens, lungs, lymph nodes, Peyer’s patches and sera from 
wild-type, CCL22 KO heterozygous and CCL22 KO homozygous mice. 
Subsequently, we measured CCL22 protein levels in organ lysates and sera 
by ELISA. Indeed, no CCL22 was detectable in all analyzed lysates and in the 
serum of CCL22 homozygous knockout mice. 
In addition, a significant intermediate down-regulation in spleens, lungs 
and sera of heterozygous CCL22 KO mice compared to wild-type mice was 
observed (Figure 38). We also measured CCL17 levels in CCL22 KO mice by 
ELISA. Since CCL17 is the only CCR4 ligand apart from CCL22, we wanted 
to exclude that the lack of CCL22 in CCL22 KO mice is compensated via 
up-regulated CCL17 expression. However, no differences in CCL17 levels 
were observed between wild-type and CCL22 KO mice (data not shown). In 
summary, the newly generated CCL22 knockout mice completely lack CCL22 
expression. 
Since DCs are the main source of intratumoral CCL22, tumors from CCL22 
KO mice are expected to lack CCL22. This in turn should lead to reduced 
amounts of tumor-infiltrating Tregs and thereby reduced tumor growth in 
CCL22 KO mice. However, the accuracy of this hypothesis needs to be verified 
in upcoming tumor experiments.
Discussion
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4. Discussion
The mechanisms by which tumor cells create a suppressive environment to 
escape from an anti-tumor immune reaction are complex and poorly under-
stood. However, recent studies have shown that recruitment of certain 
immune cells of the innate and adaptive immune system can help the tumor 
to establish an immunosuppressive milieu. In this context one very impor-
tant cell type are regulatory T cells. Increased amounts of Tregs in cancer 
patients as well as the suppressive characteristics of Tregs support a role for 
these cells in cancer-induced immunosuppression. 
Indeed, in the last decade several reports have associated high Treg tumor 
infiltration with increased tumor progression and decreased patient 
survival. In breast carcinoma high Treg tumor infiltration predicts aggres-
sive tumor growth and poor patient survival (Bohling and Allison, 2008; 
Bates et al., 2006). A negative impact of Tregs on patient survival is also 
reported for lung, pancreas, gastric, liver and ovarian carcinoma (Petersen 
et al., 2006; Woo et al., 2001; Liyanage et al., 2002; Mizukami et al., 2008; 
Hiraoka et al., 2006; Kobayashi et al., 2007; Gao et al., 2007; Curiel et al., 
2004). Nevertheless, the effects of Tregs on tumor progression could vary 
in different tumor entities (Faget et al., 2011). In B cell lymphoma or head 
and neck carcinoma higher Treg numbers correlate with better outcome for 
tumor patients (Tzankov et al., 2008; Badoual et al., 2006). Overall, in the 
majority of reports intratumoral Tregs are associated with a poor prognosis 
for cancer patients.
The trafficking of immune cells into the tumor tissue is regulated by the 
intratumoral expression of different chemokines. Identifying the chemo-
kines involved in this trafficking is very important in order to establish 
targets for immunotherapy. Since the chemokine CCL22 is a potent attractor 
of Tregs, this chemokine could be involved in Treg tumor infiltration and 
thereby inducing intratumoral immunosuppression.
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4.1 DCs are the main producer of intratumoral CCL22
We observed high levels of the chemokine CCL22 in tumor lysates of murine 
colon carcinoma, melanoma, mammary cancer and pancreatic cancer. In 
analogy to mice high CCL22 expression levels in several human tumors have 
been reported. For instance, immunohistochemical analyses of primary breast 
tumor sections revealed high intratumoral CCL22 levels in tumor patients 
(Anz et al., 2011; Gobert et al., 2009). Furthermore, high intratumoral CCL22 
expression was observed in human Hodgkin lymphoma, B cell non-Hodgkin 
lymphoma, gastric cancer and ovarian carcinoma (Ishida et al., 2006; Yang et 
al., 2006; Mizukami et al., 2008; Curiel et al., 2004). Although many reports 
of intratumoral CCL22 expression can be found in the literature, there are 
still controversies about the cellular source of intratumoral CCL22. Several 
authors argue that tumor cells are the main source of intratumoral CCL22 
in humans and mice. Only few reports convincingly identified tumor cells as 
CCL22 producers. Here, human breast cancer cells were shown to produce 
CCL22 in vitro and in vivo (Anz et al., 2011; Faget et al., 2011). However, in 
human breast cancer not only tumor cells but also DC-shaped infiltrating 
immune cells produce remarkable amounts of CCL22 (Anz et al., 2011; Gobert 
et al., 2009). In ovarian cancer tumor cells together with macrophages were 
hypothesized to be the source of intratumoral CCL22 (Curiel et al., 2004). 
In contrast to these reports we observed no CCL22 expression by tumor cell 
lines in vitro. It is reported that murine and human DCs are the most potent 
producers of CCL22 in healthy subjects (Tang and Cyster, 1999; Vulcano et al., 
2001). Additionally, beside other chemokines such as CCL16, CCL17, CCL18 and 
CX3CL1 intratumoral DCs can produce CCL22 (Raman et al., 2007). Thus, we 
hypothesized that DCs could be the main producer of intratumoral CCL22. 
Indeed, we identified intratumoral murine DCs as the exclusive source of 
CCL22 in the tumor tissue. For our experiments we used CD11c as a DCs marker 
since CD11c is expressed on all defined DC subsets in mice. We observed very 
high CCL22 mRNA and protein expression levels in DC from freshly dissected 
tumors. In contrast, CCL22 was barely expressed in the DC-depleted fraction. 
After DC depletion no CCL22 production by tumor cells or other immune cells 
was detected in tumor single cell suspensions indicating that intratumoral DCs 
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are the exclusive CCL22 producers in murine cancer. Unlike previous reports 
our findings demonstrate that tumor cells do not produce CCL22. In this study 
we investigated the CCL22 expression profile of melanoma and pancreatic 
cancer. In other tumor types the situation could be different. In conclusion, 
our findings show that CCL22 expression by tumor cells is not a common char-
acteristic of all tumor types, but rather an acquired property of certain tumor 
types such as breast cancer. Furthermore, DCs could have an important role in 
establishing an immunosuppressive tumor microenvironment and could serve 
as target for tumor immunotherapies. 
4.2 CCL22 affects tumor growth and survival
As previously described, high intratumoral CCL22 expression is observed in 
many different tumor types in humans and in mice. According to this frequent 
occurrence of CCL22 in different types of tumors, we hypothesized that this 
chemokine could influence tumor development and growth. In healthy 
subjects CCL22 has been reported to be a very selective and potent Treg 
attractor (Iellem et al., 2001). Consistent with these findings, the only known 
receptor for CCL22, which is CCR4, is highly expressed on Tregs compared to 
other T cell subtypes (Imai et al., 1998). Thus, intratumoral CCL22 could be 
involved in Treg recruitment into the tumor tissue. 
Indeed, in several publications a dependency between intratumoral CCL22 
expression and Treg infiltration was observed. For instance, in a non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mouse model 
human ovarian tumors which are known to express high levels of intratu-
moral CCL22 were highly infiltrated by adoptively transferred human Tregs. 
After treating these mice with an anti-CCL22 antibody, a significant decrease 
in Treg tumor infiltration was observed, whereas the migration of other 
T cell subtypes was not affected (Curiel et al., 2004). In human gastric cancer 
samples flow cytometry analyses of single cells, derived from tumor tissues, 
revealed a significant correlation between the frequency of intratumoral 
CCL22 and tumor-infiltrating Tregs (Mizukami et al., 2008). 
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We and other groups have observed high intratumoral levels of the potent 
Treg attractor CCL22 in several types of tumors. However, until now 
the impact of CCL22 expression on tumor growth and overall survival is 
completely unknown. In this study we used a novel generated murine tumor 
cell line with inducible intratumoral CCL22 expression to investigate the 
exclusive effect of CCL22 on tumor progression. With this rtTA-CCL22-CT26 
tumor cell line we showed that an induced over-expression of CCL22 in the 
tumor tissue of tumor-bearing mice significantly promotes tumor growth. In 
addition, the overall survival of these mice was reduced compared to mice 
with low intratumoral CCL22 expression. Furthermore, presence of CCL22 
allowed tumor development even if suboptimal doses of tumor cells were 
injected. Thus, we showed here for the first time a direct impact of intratu-
moral CCL22 on tumor development, growth and overall survival supporting 
a role for CCL22 in cancer-induced immunosuppression. These findings indi-
cate that CCL22 could be a promising target for new anti-cancer drugs. 
Antagonizing CCL22 with antibodies or siRNA could have the potential to 
promote anti-tumor immunity.
4.3 IFN-α induces TLR-mediated CCL22 suppression
As described earlier, in previous studies done by Dr. David Anz we observed a 
significant suppression of intratumoral CCL22 after TLR treatment of tumor-
bearing mice (unpublished data). We observed this suppressive effect in T-cell 
lymphoma, colon carcinoma, melanoma and pancreatic cancer with different 
TLR ligands such as CpG (TLR9), poly (I:C) (TLR3 and MDA-5) and R848 (TLR7). 
These findings indicate that intratumoral CCL22 regulation by TLR ligands is 
a general phenomenon and not specific for a certain TLR ligand or tumor 
entity. However, the precise impact of this regulation and the mechanism 
that induces CCL22 suppression are unclear. 
In general, TLR ligand binding leads to TLR activation. Thereby, the expres-
sion of many different genes is induced in a complex signalling cascade. 
One very abundantly induced cytokine, especially after TLR3, 4, 7 or 9 and 
RLR activation, is IFN-α (Iwasaki et al., 2004; Hertzog et al.; 2003). Strikingly, 
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we identified this cytokine to be the main mediator of TLR ligand-induced 
CCL22 suppression. We observed a highly suppressive effect of IFN-α on 
CCL22  secretion of freshly isolated intratumoral leukocytes. We saw the same 
effect after treating intratumoral DCs, the exclusive source of intratumoral 
CCL22 in murine melanoma and pancreatic cancer as shown above, with IFN-α 
indicating that IFN-α directly affects DCs. Additional to IFN-α we observed 
a significant CCL22 suppression after stimulating tumor-infiltrating immune 
cells with IL-10, IL-12 or IFN-γ. However, previous work done by Raffael Thaler 
(Department of Clinical Pharmacology, LMU) showed that the CpG-mediated 
suppression of CCL22 is not abolished in IL-10, IL-12 or IFN-γ knockout mice 
(unpublished data), indicating that these cytokines alone are not responsible 
for the TLR-induced suppression of CCL22.
In conclusion, our findings indicate that TLR stimulation initiates IFN-α 
expression by DCs themselves and other immune cells, and IFN-α in turn 
directly suppresses CCL22 secretion in intratumoral DCs. In addition to 
these ex vivo experiments we confirmed the impact of IFN-α on CCL22 
suppression after TLR activation in IFNAR mice. In TLR ligand-treated 
IFNAR mice, which lack a functional type I interferon receptor, the effect 
of IFN-α was abrogated, and thereby also the suppression of intratumoral 
CCL22 was abolished. Indeed, the TLR ligand-induced decrease of intra-
tumoral CCL22 expression was not only blocked in IFNAR mice, but even 
increased. As shown by Vulcano et al. and Penna et al. the stimulation 
with certain TLR ligands such as LPS could induce the CCL22 expression 
of in vitro differentiated DCs (Vulcano et al., 2001; Penna et al., 2002). In 
IFNAR mice this in vitro observation could be responsible for the measured 
increase of CCL22 expression after poly (I:C) treatment. Since the suppres-
sive effect of IFN-α on CCL22 expression is abrogated in IFNAR mice, the 
impact of TLR-induced CCL22 induction seems to prevail in these mice. Due 
to limited available numbers of IFNAR mice we could verify the effect of 
only one TLR stimulus on CCL22 suppression in tumor-bearing IFNAR mice. 
Since we wanted to analyze the contribution of IFN-α to TLR-mediated 
CCL22 suppression we used poly (I:C), a TLR ligand that is known to induce 
strong IFN-α production in mice (Matsumoto and Seya 2008), for these 
limited experiments. However, the effect of CpG and other TLR ligands on 
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CCL22 suppression in IFNAR remains to be elucidated and should be veri-
fied in follow-up experiments.
In this study we have demonstrated for the first time that TLR-mediated 
CCL22 suppression is IFN-α-induced. The effects of IFN-α are very diverse. 
Initially discovered as an antiviral protein, many studies have revealed the 
impact of IFN-α in modulating the innate and adaptive immune reaction in 
response to a variety of pathogens (Theofilopoulos et al., 2005). IFN-α can 
induce anti-angiogenesis, immune regulation, cell differentiation and apop-
tosis in different types of human tumors (Tarhini et al., 2012; Kirkwood et al., 
2002). Especially DCs respond to IFN-α treatment. Several studies revealed an 
INF-α-promoting effect on the polarization, maturation, survival and antigen 
cross-presentation of DCs which in turn enhances anti-cancer therapy (Tarhini 
et al., 2012; Kirkwood et al., 2002; Wang et al., 2007; Paquette et al., 1998; 
Krown et al., 1984). Minasian and others have revealed that IFN-α could have 
a beneficial effect in the therapy of human cancers such as renal cell cancer 
and melanoma (Minasian et al., 1993; Kirkwood et al., 2002; Takaoka et al., 
2003; Melichar et al., 2012). Compatible with these reports our finding also 
indicates a pro-therapeutic effect of INF-α in tumor treatment. This aspect 
could be considered in order to find new fields of application and identifying 
appropriate cancer patient subsets for IFN-α treatment. Since only a very small 
cancer patient cohort profits of an INF-α therapy and so far a predictor of 
response has not been found CCL22 could possibly serve to select appropriate 
cancer patient subsets (Tarhini et al., 2012; Kirkwood et al., 2012). Our results 
imply that patients with high intratumoral CCL22 levels could have a higher 
benefit from IFN-α therapy. Thus, in this study we revealed new aspects for 
an IFN-α-mediated anti-cancer therapy.
4.4 CCL22 suppression is an important component of TLR- 
 initiated tumor regression
In the past few years many new approaches for anti-cancer immunotherapy 
were developed, one of these are synthetic TLR ligands. With TLR ligands 
the innate immune system can be activated and the tumor-induced immune 
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suppression attenuated (Kanzler et al., 2007). The TLR9 ligand CpG, for 
instance, reduces tumor growth and increases overall survival of tumor-
bearing mice (Heckelsmiller et al., 2002; Houot and Levy, 2009; Krieg, 2008). 
Beside the broadly described therapeutic effects and prospects of TLR ligands 
in literature the precise mechanisms that mediate TLR-induced anti-tumor 
immunity are still poorly understood. As described above we observed a 
significant suppression of intratumoral CCL22 after TLR treatment of tumor-
bearing mice. In consideration of the tumor-growth-promoting effects of 
CCL22 we observed in this study, intratumoral CCL22 suppression could be an 
important component of TLR-initiated tumor regression. 
In this study we were able to abolish the therapeutic effect of TLR treat-
ment by preventing CpG-induced intratumoral CCL22 suppression. This was 
achieved by CCL22 over-expression in the tumor tissue of tumor-bearing 
mice. Thus, we demonstrated for the first time that CCL22 has a direct effect 
on TLR-mediated immunotherapy. According to our results, the suppres-
sion of CCL22 is therefore an important mechanism for TLR-induced tumor 
regression. Additionally, by counterbalancing the intratumoral suppres-
sion of CCL22 in TLR ligand-treated tumor-bearing mice, no decrease in 
intratumoral Treg levels was observed.
In previous experiments done by Dr. David Anz and Dr. Viktor Kölzer it was 
shown that TLR treatment not only reduces tumor-associated CCL22 levels, 
but also decreases the number of tumor-infiltrating Tregs (unpublished 
data). In addition, we and others observed a clear correlation between 
intratumoral CCL22 and Treg levels in the tumor tissue (Mizukami et al., 
2008). Furthermore, in several studies a promoting impact of tumor-asso-
ciated Tregs on tumor progression has been reported. These findings indi-
cate that intratumoral CCL22 mediates Treg tumor infiltration and thereby 
increases tumor progression. Thus, the benefit of TLR-induced CCL22 
suppression is potentially mediated through an inhibition of Treg immi-
gration into the tumor. Figure 33 schematically illustrates the proposed 
mechanism of TLR ligand-induced tumor-associated CCL22 suppression 
and the assumed effects on tumor progression. 
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Figure 39: Overview of the proposed mechanisms in this study. This illustration shows the 
proposed mechanism of TLR ligand-mediated tumor regression. TLR stimulation activates IFN-α	secre-
tion by immune cells such as DCs. Via autocrine or paracrine signalling IFN-α suppresses CCL22 
expression. This in turn blocks CCL22-mediated Treg recruitment into the tumor tissue. Thereby, 
the number of intratumoral Tregs is reduced, and Treg-induced immune suppression is abolished. 
Cytotoxic T cells are no longer suppressed and can actively kill tumor cells, whereby an anti-tumor 
immune reaction is induced.
4.5 CCL22 is a promising anti-tumor drug target
Manipulating the immune system has become a very promising approach for 
anti-tumor therapy in the last years. Many potential new targets have been 
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identified. However, new therapeutic approaches such as patient vaccination 
with tumor-specific antigens or adoptive T cell transfer of tumor antigen-
specific cytotoxic T cells fail in the majority of cases to cure cancer patients 
due to tumor escape strategies. One of the major problems in this purpose is 
tumor-induced immune suppression. Therefore, circumventing this immune 
suppression is a very important step in achieving an efficient anti-tumor 
therapy. For this purpose Tregs seem to be a target with good prospects. 
These cells are known to mediate immune suppression and are associated with 
poor prognosis for cancer patients in many tumor entities. Indeed, in many 
experiments the therapeutic effects of Treg depletion or blockage in cancer 
patients have been confirmed. For instance, the depletion of Tregs by anti-
CD25 depletion antibody enhanced a vaccine-mediated anti-tumor immunity 
in cancer patients (Dannull et al., 2005; Onizuka et al., 1999; Shimizu et al., 
1999). The dual use of CTLA-4 blocking antibody and CD25 depletion anti-
body also showed promising results for abolishing tumor-induced immune 
suppression (Sutmuller et al., 2001). In patients with metastatic melanoma 
ipilimumab, a CTLA-4 blocking antibody, improved overall survival (Hodi et 
al., 2011). 
However, in these approaches not only intratumoral Tregs are depleted or 
blocked, but also all other Tregs which in turn often caused autoimmunity. 
In addition, Treg depletion always involves the depletion of other anti-tumor 
immunity promoting immune cells such as cytotoxic T lymphocytes since 
precise Treg surface marker are still missing. For instance, CD25 depletion 
antibody also depletes cytotoxic T lymphocytes which up-regulate CD25 after 
activation (Phan et al., 2003; Jones et al., 2002). To minimize side effects, new 
approaches must be investigated. One very promising alternative would be 
the blockade of intratumoral Treg infiltration. By blocking the infiltration of 
Tregs into the tumor, only the intratumoral immune suppressive effect of 
these cells would be abrogated and not their important function as suppres-
sors of autoimmunity. In this study we showed that the chemokine CCL22 
seems to have this potential. This chemokine is a very specific and potent Treg 
attractor (Iellem et al., 2001). As shown above CCL22 is up-regulated in colon 
carcinoma, melanoma, mammary cancer and pancreatic cancer. Furthermore, 
high intratumoral CCL22 expression is associated with increased Treg tumor 
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infiltration (Mizukami et al., 2008). In addition, we showed here for the first 
time that CCL22 can accelerate tumor growth and reduce overall survival in 
tumor-bearing mice. 
Beside Treg recruitment to the tumor tissue, CCL22 could have additional 
unknown tumor-promoting effects. By blocking the function of this chemo-
kine, these effects could be abrogated and anti-tumor immunity promoted. 
Therefore, the development of a CCL22 blocking antibody for further in 
vivo experiments will be the next step to verify this assumption. In addition, 
CCR4 and CCL22 KO mice could deliver further insights into the mechanism 
of CCL22-mediated Treg tumor infiltration and the tumor-promoting effect 
of CCL22. Since CCR4 is the exclusive receptor of CCL22 in CCR4 KO mice a 
CCL22-mediated cell migration is block. Thus, in these mice less Tregs should 
be present in the tumor tissue which in turn would confirm that CCL22 is 
involved in the attraction of Tregs into tumors. Furthermore, CCL22 KO mice 
could be used to analyze additional effects of CCL22 on tumor growth in 
more detail. We identified DCs and not tumor cells as the producer of intra-
tumoral CCL22. Thus, in CCL22 KO mice no CCL22 should be expressed in the 
tumor tissue and therefore the tumor-promoting effect of CCL22 would be 
blocked. This in turn should result in a decrease of tumor growth. Since CCR4 
and CCL22 KO mice as well as a CCL22 blocking antibody were not available 
until the end of my thesis these experiments still needs to be done. Taken 
together, the results of previous experiments and of this study illustrate that 
the chemokine CCL22 could be a promising target for anti-tumor therapy. 
In conclusion, investigating the function of intratumoral CCL22 seems to have 
the potential to improve the outcome of current anti-tumor therapies. With 
the presented results we were able to gain new insights into this field and 
provided the basis for further experiments aiming to find new anti-cancer 
drugs.
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5. Summary
An effective anti-cancer therapy requires that the tumor-induced immune 
suppressive environment is abolished. Without bypassing this suppressive 
 milieu, most immunotherapies show only poor benefits for cancer patients. 
In order to escape from the host immune system, the tumor capitalizes on 
the protective immune mechanism of the host. One cell type involved in this 
process are regulatory T cells. Increased amounts of regulatory T cells in cancer 
patients as well as the suppressive characteristics of these cells support an 
important role for regulatory T cells in cancer-induced immunosuppression. 
The aim of this study was to investigate the role of the chemokine CCL22 in 
tumor-induced immune suppression. In previous studies we demonstrated that 
in murine cancer high levels of CCL22 are expressed. Since CCL22  specifically 
attracts regulatory T cells, we hypothesized that intratumoral CCL22 expres-
sion is one of the mechanisms used by tumors to escape the host immune 
system.
In contrast to breast cancer in which CCL22 is expressed by tumor cells, we 
 identified intratumoral dendritic cells as the main producers of tumor-asso-
ciated CCL22 in melanoma and pancreatic cancer. By using a murine colon 
cancer tumor cell line with inducible CCL22 expression, a clear impact of 
intratumoral CCL22 on tumor genesis was observed. In mice tumor growth 
was increased and overall survival decreased after induction of intratumoral 
CCL22 indicating that high intratumoral CCL22 levels are associated with poor 
 prognosis. 
Treating tumor-bearing mice with immune activating Toll-like receptor (TLR) 
ligands reduces tumor growth and increases overall survival. In previous 
studies of our group it was shown that TLR activation suppresses intratu-
moral CCL22 expression. We demonstrated here for the first time that this 
TLR ligand-induced reduction of intratumoral CCL22 is mediated by IFN-α, a 
 cytokine released by immune cells after TLR stimulation. Furthermore, when 
suppression of intratumoral CCL22 was counterbalanced by using a tumor 
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cell line with inducible CCL22 expression, the therapeutic benefit of TLR 
 ligands in mice was abolished. In addition, the previously described reduction 
of intra tumoral regulatory T cell numbers by TLR activation was reversed. 
These results indicate that TLR ligands lead to tumor regression at least 
partially by suppressing intratumoral CCL22 expression which in turn blocks 
the  infiltration of immuno suppressive regulatory T cells into the tumor. Thus, 
CCL22 suppression is a crucial part of TLR-induced tumor regression.
In conclusion, this study illustrates the important role of CCL22 in tumor 
 development and clinical outcome. CCL22 represents an essential chemokine 
in recruiting regulatory T cells into the tumor tissue and inducing an immune 
suppressive tumor environment. Thus, targeting this chemokine by treating 
 cancer  patients with IFN-α or CCL22-blocking antibody could be a promising 
 approach for an efficient anti-cancer immunotherapy. 
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6. Zusammenfassung
Für eine effektive Anti-Tumor-Therapie ist es erforderlich das immunsuppres-
sive Milieu des Tumors außer Kraft zu setzen. Ohne eine Aufhebung dieses 
suppressiven Milieus zeigen die meisten Immuntherapien nur geringe Erfolge 
in der Bekämpfung von Tumorerkrankungen. Um einer effektiven Immunre-
aktion zu entgehen, macht sich der Tumor bestimmte Schutzmech anismen des 
Immunsystems zunutze. Eine Zellart, die an diesem Prozess beteiligt ist, sind 
regulatorische T Zellen. Erhöhte Zahlen an regulatorischen T Zellen in Tumor-
patienten, sowie die immunsuppressiven Eigenschaften dieser Zellen, deuten 
darauf hin, dass regulatorische T Zellen entscheidend zu der  Etablierung eines 
immunsuppressiven Tumormileus beitragen.
Das Ziel dieser Doktorarbeit war es, den Einfluss des Chemokins CCL22 
auf die tumor-induzierte Immunsuppression zu erforschen. In Vorarbeiten 
unserer Arbeitsgruppe konnten wir zeigen, dass in murinen Tumoren CCL22 
in erhöhtem Maße exprimiert wird. Da CCL22 effektiv regulatorische T Zellen 
anlockt, vermuteten wir, dass die tumorassoziierte CCL22-Expression entschei-
dend an der Entstehung eines immunsuppressiven Tumormilieus beteiligt ist. 
Im Gegensatz zu Brusttumoren, in denen die Tumorzellen selbst CCL22 produ-
zieren, konnten wir im murinen Melanom und Pankreaskarzinom dendritische 
Zellen als die Hauptproduzenten von intratumoralem CCL22 identifizieren. 
Mit Hilfe einer murinen Kolontumorzelllinie, die induzierbar CCL22 produ-
ziert, wurde ein klarer Zusammenhang zwischen intratumoralem CCL22 und 
Tumorwachstum beobachtet. Nach Induktion der CCL22-Produktion war das 
Tumorwachstum in Mäusen beschleunigt und das Gesamtüberleben signifi-
kant verringert. Diese Daten verdeutlichen, dass hohe CCL22 Konzentra tionen 
im Tumor mit einer schlechten Prognose verbunden sind.
Eine Behandlung von tumor-tragenden Mäusen mit Toll-like-Rezeptor-
Liganden, die eine aktivierende Wirkung auf das Immunsystem haben, führt 
zu einer Tumorregression und steigert das Gesamtüberleben der behandelten 
Mäuse. Frühere Experimente unserer Arbeitsgruppe demonstrierten, dass 
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TLR-Liganden die Expression von tumor-assoziiertem CCL22  supprimieren und 
die Infiltration von regulatorischen T Zellen in den Tumor reduzieren. In der 
vorliegenden Arbeit konnte erstmalig gezeigt werden, dass die TLR-Liganden-
induzierte CCL22-Reduktion durch IFN-α, ein Zytokin, das Immunzellen nach 
TLR-Stimulation sezernieren, vermittelt wird. Durch die Verwendung von 
Tumorzellen mit induzierbarer CCL22-Expression konnte des Weiteren belegt 
werden, dass eine Aufhebung der TLR-vermittelten CCL22 Suppression den 
thera peutischen Effekt von TLR-Liganden abschwächt. Darüber hinaus wurde 
die TLR-induzierte Reduktion von tumorinfiltrierenden, regulatorischen 
T Zellen durch die  Antagonisierung der CCL22-Suppression aufgehoben. Diese 
Ergebnisse deuten darauf hin, dass die TLR-Liganden-induzierte Tumorregres-
sion teilweise durch eine Suppression der intratumoralen CCL22 Expression 
vermittelt wird, die wiederum die Tumorinfiltration von immunsuppressiven, 
regulatorischen T Zellen verringert. Die Suppres sion von tumorassozi-
iertem CCL22 ist somit ein entscheidender Bestandteil der TLR-induzierten 
 Tumorregression.
Die Erkenntnisse dieser Arbeit verdeutlichen die wichtige Rolle von CCL22 
bei der Tumorentstehung sowie der Prognose von unterschiedlichen Tumor-
entitäten. CCL22 ist ein Chemokin, das entscheidend an der Rekrutierung 
von regulatorischen T Zellen in den Tumor und dadurch an der Etablierung 
eines immunsuppressiven Tumormilieus beteiligt ist. Aus diesem Grund 
könnten neue Therapieansätze, die spezifisch auf eine Regulierung von intra-
tumoralem CCL22 ausgelegt sind, einen entscheidenden Beitrag im Kampf 
gegen Krebs leisten. Ein vielversprechender Ansatz ist somit zum Beispiel die 
Behandlung von Tumorpatienten mit IFN-α oder einem CCL22-blockierenden 
Antikörper.
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8. Appendices
8.1 PCR primer list
All primers were obtained from Metabion (Planegg, Germany) or Eurofins 
MWG (Ebersberg, Germany).
CCL22-For-EcoRI  5’-ATTAGAATTCATGGCTACCCTGCG-3’
CCL22-For-EcoRI  5’-ATTAGAATTCCTAGGACAGTTTATG-3’
CCL22-For-NotI  5’-ATT AGC GGC CGC ATG GCT ACC CTG CGT GTC-3’
CCL22-Rev-SalI  5’-ATT AGT CGA CCT AGG ACA GTT TAT GGA GTA 
G-3’
pTRE-Seq-For   5’-AGG CGT ATC ACG AGG CCC TTT CGT-3’
pTRE-Seq-Rev  5’-TAT TAC CGC CTT TGA GTG AGC TGA-3’
pTRE-tight-Rev  5’-CGC CTT TGA GTC AGC TGA TAC CGC TCG CCG-3’
TRE-F    5’-TAG GCG TGT ACG GTG GGA G-3’
TRE-R    5’-CTC TAC AAA TGT GGT ATG GC-3’
rtTA-F    5’-CAA TCG AGA TGC TGG ACA GG-3’
rtTA-R   5’-CAG CAG GCA GCA TAT CAA GG-3’
TDF    5’-GCCCTTAGTAGTGTCTGCTTTC-3’
TDR    5’-GCTCCTTGTTAGCAAGTCAGC-3’
NeoinF   5’-TTCGGCTATGACTGGGCACAACAG-3’
NeoinR   5’-TACTTTCTCGGCAGGAGCAAGGTG-3’
8.2 Quantitative real-time PCR primer list
All primers were obtained from Metabion (Planegg, Germany) or Eurofins 
MWG (Ebersberg, Germany). Primers and probes were designed by using the 
online Roche Assay Design Center.
RT-PCR-CCL22-For  5’-TCT TGC TGT GGC AAT TCA GA-3’
RT-PCR-CCL22-Rev  5’-GAG GGT GAC GGA TGT AGT CC-3’
Roche Probe for CCL22 #84
RT-PCR-CD11c-For  5’-ATG GAG CCT CAA GAC AGG AC-3’
RT-PCR-CD11c-Rev  5’-GGA TCT GGG ATG CTG AAA TC-3’
Roche Probe for CD11c #20
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RT-PCR-rtTA-For  5’-CTT TTC GGC CTG GAA CTA ATC-3’
RT-PCR-rtTA-Rev  5’-GCC GCT TTC GCA CTT TAG-3’
Roche Probe for rtTA #80
RT-PCR-HPRT-For  5’-GGA GCG GTA GCA CCT CCT-3’
RT-PCR-HPRT-Rev  5’-CTG GTT CAT CAT CGC TAA TCA C-3’
Roche Probe for HPRT #69
8.3 Sequencing data of pTRE-Tight CCL22 vector
Primer for Sequencing: pTRE-Seq-Rev; CCL22 sequence is shown in blue letters. 
Clone 1
5’-CGTTTTCTGGGTGAGGCAAAAAAACAGAGCCAAATGCGCAAAAACGATA-
AGGGGCGGACACCGAATGGTGGATTACTCCATACTCTCCGTTTTCAATATT-
TATTGAAGCATTTATCAGGCTTATTGTCTCCATGAGCGGATACATATTT-
GAATGTATTTAGAAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC-
GAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATA-
AAAATAGGCGTATCACGAGGCCCTTTCGTCTTCACTCGAGTTTACTCCCTAT-
CAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGA-
ACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTT-
TACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGT-
GATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATAGAGAACGTATGTC-
GAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTACG-
GTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTG-
GAGAATTCGAGCTCGGTACCCGGGGATCCTCTAGTCAGCTGACGCGTGCTAGC-
GCGGCCGCATGGCTACCCTGCGTGTCCCACTCCTGGTGGCTCTCGTCCTTCTT-
GCTGTGGCAATTCAGACCTCTGATGCAGGTCCCTATGGTGCCAATGTGGAAGA-
CAGTATCTGCTGCCAGGACTACATCCGTCACCCTCTGCCATCACGTTTAGT-
GAAGGAGTTCTTCTGGACCTCAAAATCCTGCCGCAAGCCTGGCGTTGTTTT-
GATAACCGTCAAGAACCGAGATATCTGTGCCGATCCCAGGCAGGTCTGGGT-
GAAGAAGCTACTCCATAAACTGTCCTAGGTCGACGATATCTCTAGAGGATCATA-
ATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCA-
CACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTT-
GTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCA-
CAAATAAAGCATTTTTTTCACTGCCTCGAGCTTCCTCGCTCACTGACTCGCTGC-
GCTCGTCGTCGCTGCGGCAGACCGG-3’
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Clone 2
5’-CAGGGCGTTTTTCTGGTGAGGCAAAAATACGGAAGGCAAATGCG-
CAAAAGAATACGGCGACACGTAATGTGATACTCATACTCTCTTTTGCAC-
TATATTGAGCAATTTATCAAGGCTAATGTCTCATGAGCGGATACATATTC-
GATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC-
GAAAAGTGCCACCTGACGTCTAAGAAAGCCATTATTATCATGACATTA-
ACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCACTCGAGTT-
TACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGT-
GATAGAGAACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTC-
GAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGT-
GATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATAGAGAACGTATGTC-
GAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTACG-
GTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTG-
GAGAATTCGAGCTCGGTACCCGGGGATCCTCTAGTCAGCTGACGCGTGCTAGC-
GCGGCCGCATGGCTACCCTGCGTGTCCCACTCCTGGTGGCTCTCGTCCTTCTT-
GCTGTGGCAATTCAGACCTCTGATGCAGGTCCCTATGGTGCCAATGTGGAAGA-
CAGTATCTGCTGCCAGGACTACATCCGTCACCCTCTGCCATCACGTTTAGT-
GAAGGAGTTCTTCTGGACCTCAAAATCCTGCCGCAAGCCTGGCGTTGTTTT-
GATAACCGTCAAGAACCGAGATATCTGTGCCGATCCCAGGCAGGTCTGGGT-
GAAGAAGCTACTCCATAAACTGTCCTAGGTCGACGATATCTCTAGAGGATCATA-
ATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCA-
CACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTT-
GTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCA-
CAAATAAAGCATTTTTTTCACTGCCTCGAGCTTCCTCGCTCACTGACTCGCTGC-
GCTCGTCGTACGCTGCGGCAGACCGT-3’
8.4 Sequencing data of pTRE-CCL22 mouse
Primer for Sequencing: pTRE-Seq-Rev; TRE promoter sequence is shown in 
green letters, CCL22 sequence in light blue letters, MCS in black letters and 
SV40polyA sequence in blue letters. The observed transition point mutation 
(C κ	T) is part of the MCS and is indicated by a red letter.
pTRE-CCL22 mouse
5’-CTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTAT-
CAGTGATAGAGAACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTAT-
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GTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTAT-
CAGTGATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATAGAGAACGTAT-
GTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTAC-
GGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTG-
GAGAATTCGAGCTCGGTACCCGGGGATCCTCTAGTCAGCTGACGCGTGCTAGC-
GCGGCCGCATGGCTACCCTGCGTGTCCCACTCCTGGTGGCTCTCGTCCTTCTT-
GCTGTGGCAATTCAGACCTCTGATGCAGGTCCCTATGGTGCCAATGTGGAAGA-
CAGTATCTGCTGCCAGGACTACATCCGTCACCCTCTGCCATCACGTTTAGT-
GAAGGAGTTCTTCTGGACCTCAAAATCCTGCCGCAAGCCTGGCGTTGTTTT-
GATAACCGTCAAGAACCGAGATATCTGTGCCGATCCCAGGCAGGTCTGGGT-
GAAGAAGCTACTCCATAAACTGTCCTAGGTCGACGATAT T TCTAGAGGAT-
CATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCA-
CACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTT-
GTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCA-
CAAATAAAGCATTTTTTTCACTGCCTCGAGCTTCCTCGCTCACT-3’
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8.5 Abbreviations
A
APC   Antigen-presenting cell
aa  Amino acid
B
bp  Base pairs
BrdU  5’-Bromo-2’-deoxyuridine
C
CCL  Chemokine (C-C motif) ligand
CCR   Chemokine receptor
cDNA   Copy-desoxyribonucleic acid
CpG   Oligonucleotide with cytosine-(phosphate)-guanine motifs
CTLA-4 T lymphocyte-associated antigen 4
D
cDC  Conventional dendritic cell
DC  Dendritic cell
DMEM  Dulbecco's modified Eagle´s medium
DMSO  Dimethyl sulfoxide
DNA   Desoxyribonucleid acid
ds   Double-stranded
pDC  Plasmacytoid dendritic cell
E
EDTA   Ethylenediamine-tetraacetic acid
EGFR  Epidermal growth factor receptors
ELISA   Enzyme-linked immunosorbent assay
F
FACS   Fluorescent-activated cell sorting
FCS   Fetal calf serum
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FITC   Fluorescein isocyanate
FOXP3  Forkhead box p3
FSC   Forward scatter
G
GITR  Glucocorticoid-induced TNF receptor family-related gene
H
HET  Heterogenous
HPRT  Hypoxanthine-guanine phosphoribosyltransferase
HRP  Horseradish peroxidase
I
IFN-α  Interferon-alpha
IFN-β  Interferon-beta
IFN-γ	 	 Interferon-gamma
IFNAR  Interferon-receptor-type-1
IL   Interleukin
ip   Intraperitoneally
IRF  IFN regulatory factor
K
kb  Kilo base pairs
KO  Knockout
L
LacZ  β-Galactosidase Enzym
LAG-3  Lymphocyte activation gene-3
LN  Lymph node
LPS   Lipopolysaccharid
M
MACS  Magnetic-activated cell sorting
MAP  Activation of mitogen-activated protein
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MCS  Multiple cloning site
MDA-5  Melanoma differentiation associated gene 5
MHC   Major histocompatibility complex
mRNA  Messenger ribonucleic acid
MyD88  Myeloid differentiation primary response gene 88
N
nd   Not determined
NEAA  Non-essential amino acids
NF-кB  Nuclear factor-кB
NK cell Natural killer cell
NKT cells Natural killer T cell
ns   Not significant
O
OD  Optical density
P
PAMP  Pathogen-associated molecular pattern
PBS  Dulbecco’s Phosphate buffered saline
PCR   Polymerase chain reaction
PE   Phycoerythrin
PerCP  Peridinin chlorophyll protein
PP   Peyer’s patches
PFA   Paraformaldehyde
PRR   Pattern-recognition receptor
Q
qRT-PCR  Quantitative real-time PCR
R
RCC  Renal cell carcinoma
RIG-I   Retinoic acid-inducible gene-I
RLR  RIG-I-like receptors
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RPMI   Roswell Park Memorial Institute
RNA   Ribonucleic acid
RT   Room temperature
S
sc  Subcutaneous 
SEM   Standard error of the mean
ss   Single-stranded
SSC   Sideward scatter
T
Teff  T effector cell
TGF-β	 	 Transforming growth factor-beta
TH cell  T-helper cell
TIR   Toll/IL-1 receptor
TIRAP  TIR domain-containing adapter molecule
TLR  Toll-like receptors
TMB  Tetramethylbenzidin
TNF  Tumor necrosis factor
TRAM  TRIF-related adapter molecule
Treg   Regulatory T cell
TRIF   TIR-containing adapter inducing IFN-α
  
V
VLE   Very low endotoxin
W
wt  Wild-type 
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